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ABSTRACT
TARGETING PLASMA MEMBRANE PHOSPHATIDYLSERINE CONTENT TO
INHIBIT ONCOGENIC KRAS FUNCTION

Walaa Essam Kattan B.Sc.
Advisory Professor: John F. Hancock, ScD., M.A., M.B., B.Chir., Ph.D.

The small GTPase KRAS, which is frequently mutated in human cancers,
must be localized to the plasma membrane (PM) for biological activity. We
recently showed that the KRAS C-terminal membrane anchor exhibits exquisite
lipid-binding specificity for select species of phosphatidylserine (PtdSer). We
therefore investigated whether reducing PM PtdSer content is sufficient to
abrogate KRAS oncogenesis. Oxysterol-related binding proteins ORP5 and
ORP8 exchange PtdSer synthesized in the ER for phosphatidylinositol-4phosphate (PI4P) synthesized in the PM. We show that depletion of ORP5 or
ORP8 reduced PM PtdSer levels, resulting in extensive mislocalization of KRAS
from the PM. Concordantly, ORP5 or ORP8 depletion significantly reduced
proliferation and anchorage-independent growth of multiple KRAS-dependent
cancer cell lines, and attenuated KRAS signaling in vivo. Similarly, functionally
inhibiting ORP5 and ORP8 by inhibiting PI4KIIIα-mediated synthesis of PI4P at
the PM selectively inhibited the growth of KRAS-dependent cancer cells over
normal cells in vitro and in vivo. Hence, inhibiting KRAS function through
regulating PM PtdSer content may represent a viable strategy for KRAS-driven
cancers.
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CHAPTER 1: INTRODUCTION
This chapter is based upon:
Kattan, W. E., & Hancock, J. F. (2020). RAS Function in cancer cells: translating
membrane

biology

and

biochemistry

into

new

therapeutics. Biochemical

Journal, 477(15), 2893-2919. https://doi.org/10.1042/BCJ20190839. This article was
published open access under a Creative Commons CC and does not require permission
for re-use by authors.

1.RAS Isoforms, Structure and Posttranslational Modifications
RAS proteins are part of a superfamily of more than 150 low molecular weight
GTP binding proteins [1, 2] that include the RAB, RAN, RHO and ARF families [3]. RAS
proteins oscillate between an active GTP-bound and inactive GDP-bound state to
modulate cell survival, proliferation and differentiation [4]. RAS is activated by guanine
nucleotide exchange factors (GEFs) that facilitate GDP unloading; this promotes GTP
binding because GTP concentrations in the cell are 10-fold higher than GDP [5]. RAS
proteins possess a slow intrinsic GTPase activity [6, 7] which is enhanced 105-fold by
GTPase-activating proteins (GAPs). GTP hydrolysis returns active GTP-bound RAS to
the inactive GDP-bound ground state.
There are 3 RAS genes ubiquitously expressed in human cells. HRAS and KRAS
were first identified as oncogenes in the Harvey and Kirsten Rat Sarcoma retroviruses
[8]. NRAS was identified in transformation assays using DNA from a Neuroblastoma [9].
Due to alternative splicing, the KRAS gene generates two protein isoforms, KRAS4A and
KRAS4B (hereafter KRAS), the latter of which is generally accepted to be expressed at
higher levels [10]; however, some studies have shown that KRAS4A is equally expressed
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in a variety of cancer cell lines and human colorectal cancers [11]. The RAS isoforms
share 90% sequence homology in the G domain, which binds the guanine nucleotide
[12, 13]. The G domain comprises an effector lobe (residues 1-86) and an allosteric lobe
(residues 87-165). The effector lobe interacts with RAS effectors such as RAF and PI3K
and has two regions called Switch I (residues 30-40) and Switch II (60-76) [12] that
undergo major conformational reorganization on GTP binding [14, 15]. The GTP-bound
form exists in two states: state 1 is an open conformation that promotes nucleotide
exchange and discourages effector binding; while state 2 is a closed conformation that
encourages GTP hydrolysis and effector binding [16]. GTP binding also reorients the
RAS protein with respect to the membrane to allow for effector protein interaction [15,
17, 18]. Despite extensive sequence homology in the G-domain, the RAS isoforms differ
substantially in their C-terminal hypervariable region (HVR) (residues 166-189) which
regulates subcellular localization, trafficking and plasma membrane (PM) spatiotemporal
organization [19, 20].
All RAS proteins have a C-terminal “CAAX” sequence where C is cysteine, A is
an aliphatic amino acid and X is Methionine or Serine. Nascent RAS proteins synthesized
in the cytosol are processed by farnesyl transferase (FTase) that catalyzes the addition
of a 15-carbon (farnesyl) isoprenoid to the C-terminal cysteine [21] (Figure 1). This
modification targets RAS to the cytosolic surface of the endoplasmic reticulum (ER)
where the endoprotease RAS converting enzyme 1 (RCE1), cleaves the “AAX” tripeptide
from

the

prenylated

cysteine

[22-26].

Finally,

isoprenylcysteine

carboxyl-

methyltransferase (ICMT) methyl-esterifies the a-carboxyl group of the now C-terminal
farnesylated cysteine [27-33]. Following CAAX processing, the RAS isoforms differ in
membrane trafficking and localization due to different “second signals” in the HVR
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upstream of the processed CAAX motif [34]. The HVR of NRAS and HRAS, contain one
or two, respectively, cysteine residues that are palmitoylated by the heterodimeric Golgi
palmitoyl acyltransferase DHHC9 and GCP16 [35, 36] and are then transported to the
inner leaflet of the plasma membrane (PM) via the exocytic pathway [27, 37, 38]. The
HVR of KRAS, contains a polybasic domain of 6 contiguous lysine residues that targets
KRAS to the largely negatively-charged inner leaflet of the PM via the endosome,
bypassing the Golgi [38]. Hence, the HVR contributes to differential signaling between
RAS proteins due to different post-translational modifications these regions undergo that
dictate RAS membrane trafficking and localization [5, 19]. This can clearly be seen in
studies showing that KRAS but, not N- or HRAS, is essential for normal development in
mice [24, 39-44] and that each isoform activates a common set of effectors with varying
efficiencies in vitro [42].
RAS proteins undergo constant cycles of solubilization and membrane binding
that are required to maintain the fidelity of PM localization. Following endocytosis, HRAS
and NRAS undergo de-palmitoylation by acyl-protein thioesterase (APT) releasing the
proteins into the cytosol for recycling back to the Golgi where they are re-palmitoylated
and returned to the PM by vesicular transport via the exocytic pathway (Figure 1). PMbound KRAS also undergoes endocytosis but has different outcomes depending on the
phosphorylation state of the KRAS HVR at Ser181 by PKC and PKG2 [24, 45-49]. The
endocytic vesicle is initially rich in the anionic phospholipid phosphatidylserine (PtdSer)
but loses this asymmetry, decreasing the negative charge after endocytosis [50-53],
releasing KRAS into the cytosol. Soluble KRAS is then captured by the prenyl-binding
protein phosphodiesterase delta (PDEd) which unloads KRAS at the perinuclear region
where the Arl2 GTPase is concentrated. Arl2 interacts with PDEd inducing a
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conformational change that promotes KRAS release [49]. Non-phosphorylated KRAS is
then loaded onto PtdSer-rich recycling endosomes (REs) by electrostatic trapping for
forward transport to the PM by vesicular transport (Figure 1). By contrast, electrostatic
repulsion likely operates to prevent phosphorylated KRAS from binding to the negatively
charged membrane of the RE [54], leading to the accumulation of phosphorylated KRAS
in the cytosol and other endomembranes [5, 48, 55]. Therefore, phosphorylation of
membrane-bound KRAS does not directly trigger dissociation from the PM but rather
decreases KRAS PM content by inhibiting recycling back to the PM [48].

Figure 1. Schematic of RAS posttranslational processing, plasma membrane
targeting and recycling. Following mRNA translation in the cytosol, the three RAS
isoforms (HRAS, NRAS and KRAS) are trafficked to the PM in a series of steps in specific
subcellular localizations. HRAS and NRAS are recycled through palmitoylation4

depalmitoylation cycles; KRAS is recycled via the recycling endosome which is enriched
with PtdSer. Green and red lines indicate farnesyl and palmitate, respectively. The (+)
symbol denotes polybasic residues of the KRAS hypervariable region. FTase, farnesyl
transferase; RCE, Ras-converting enzyme 1 protease; ICMT, isoprenylcysteine
carboxylmethyltransferase;

PAT,

palmitoyl

acyl

transferase;

APT,

acyl-protein

thioesterase; PDEd, phosphodiesterase delta; Arl2, ADP-ribosylation factor-like protein
2; ER, endoplasmic reticulum; Golgi, Golgi apparatus; RE, recycling endosome; PM,
plasma membrane; -Me, methyl group. This figure was originally published in Kattan, W.
E., Chen, W., Ma, X., Lan, T. H., van der Hoeven, D., van der Hoeven, R., & Hancock,
J. F. (2019). Targeting plasma membrane phosphatidylserine content to inhibit
oncogenic KRAS function. Life Sci Alliance, 2(5). doi:10.26508/lsa.201900431.
Copyright permission granted on 21 May 2021.

2.RAS in Cancer
2.1 Mutational Profiles
The RAS genes are the most frequently mutated oncogenes in cancer [13, 56]
and as such have long been considered a drug target [5, 57, 58]. The prevalence of
mutations varies substantially across the isoforms with KRAS, NRAS and HRAS being
implicated in 85%, 12% and 3% of cancers, respectively [5, 59]. Additionally, mutational
bias between the isoforms also exists with the majority of mutations occurring at codons
12 and 61 for KRAS and NRAS, respectively, while HRAS is mutated at both these sites
at a similar frequency. Overall, the 3 oncogenic mutational hotspots in RAS genes are
G12, G13 and Q61 [13]. G12 and G13 mutations displace crucial interactions between
RAS and GAPs required to form a transition-state complex, without which an increase in
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GTPase activity cannot occur, effectively maintaining KRAS in its “on” state leading to
constitutive downstream signaling [60-62]. The Q61 mutation inhibits GTP hydrolysis of
GTP-RAS by interfering with a catalytic water molecule essential for this process [60,
61]. Together, these mutations render RAS primarily GTP-bound and relatively
insensitive to GAPs [62], with a 10-fold decrease in the rate of intrinsic GTP hydrolysis
[7, 63-65].
KRAS is the isoform predominantly mutated in human cancers and occurs in some
of the more deadly cancers in the U.S: pancreatic cancer (~90%), colorectal cancer
(~50%) and non-small cell lung cancer (~25%). These cancers originate from the
endodermal layer which correlate with comparative studies that showed that KRAS G12V
mutations lead to enhanced proliferation and inhibited differentiation of endodermal stem
cells, increasing the pool of progenitor cancer cells in these organs [66-68].
The three RAS isoforms also display discrepancy in codon usage with KRAS
primarily utilizing a rare set of codons [69, 70]. This may also explain the bias towards
KRAS mutation prevalence in cancer [71, 72], as it has been well established that
persistent activation of the MAPK pathway leads to oncogene-induced senescence and
cell death [69, 73]. Indeed, in vivo studies conducted by Pershing et al. whereby they
replaced 27 rare codons with common ones in KRAS via silent mutation, showed that
the modified KRAS gene was mutated less frequently, produced less tumors in mice after
exposure to urethane, and that these tumors had weaker oncogenic mutations. They
showed that this KRAS allele when oncogenically mutated, lead to growth arrest. Their
in vitro studied also determined that the modified allele resulted in higher expression
levels of KRAS and GTP-KRAS and MAPK signaling which inhibited proliferation of
primary lung fibroblasts. Rare codon utilization leads to lower protein translation levels
of KRAS, preventing oncogene-induced senescence but favoring proliferation when the
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gene is mutated. However, in cells resistant to oncogene-induced stress, rare codon
utilization dampens the oncogenic potential of KRAS [69]. These cells therefore utilize
alternative mechanisms to increase KRAS activity and signaling such as upregulation of
EGFR [70]. Similar to others [74], they also found that the KRAS WT allele had a tumor
suppressive function [75]. This remains to be context-specific as WT KRAS has also
been shown to support tumor growth through increased signaling [76-78], inhibiting
apoptosis [79, 80] and regulating DNA damage response [81]. One speculation is that
the WT allele has tumor suppressive roles during tumor initiation and tumor promoting
roles after the tumor has been established and is resistant to oncogene-induced stress
[70].

2.2 KRAS Effector Signaling
Multiple RAS effectors that bind GTP-RAS proteins via a RAS-binding domain
(RBD) or a RAS association (RA) domain have been described [82]. Among these, the
most important in KRAS oncogenesis are components of the RAF-MEK-ERK (MAPK)
pathway and the PI3K-AKT-mTOR pathway that promote cell proliferation and survival,
respectively [3, 13, 83].
The RAF proteins (CRAF, BRAF and ARAF) are serine/threonine kinases that, on
activation, phosphorylate and activate MEK1 and MEK2 which in turn phosphorylate and
activate ERK1 and ERK2 [84, 85]. Activated ERK1/2 then phosphorylate >200 substrates
including members of the ETS family of transcription factors and c-FOS which activates
the AP1 transcription factor. Together, these events lead to the expression of D-type
cyclins and other cell cycle regulatory proteins to promote cell cycle progression through
the G1 phase [86-90].
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Interaction of GTP-KRAS with the catalytic subunits of type I phosphatidylinositol
3-kinase (PI3K), p110a/d/g [91, 92], recruits the kinase to the PM where it phosphorylates
phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate
(PIP3) [93, 94]. PIP3 then binds to and activates the serine/threonine kinase AKT, which
phosphorylates and activates many downstream targets including the NF-κB
transcription factor involved in cell survival, and FOXOs involved in DNA damage repair
[82, 95-98]. RAS activation of PI3K is important because it mimics a PI3K-dependent
survival signal normally induced by extracellular matrix (ECM) attachment, which is lost
in cancer cells [98] (reviewed in [99]). Under normal physiological conditions, loss of ECM
attachment induces BAX translocation to the mitochondria and cytochrome c release,
leading to apoptosis [100]. PI3K signaling inhibits cytochrome c release through AKTmediated phosphorylation of I-kB kinase (IKK), releasing NF-kB, leading to the
production of anti-apoptotic proteins [101]. NF-kB activation through PI3K-RAC signaling
can attenuate the toxic effects of reactive oxygen species, modulate oxidative stress
[100, 102-104] and lead to the production of IAPs (inhibitor of apoptosis proteins)
(reviewed in [105, 106]).
In vitro experiments show that HRAS and KRAS more effectively activate the PI3K
and MAPK pathways, respectively [107, 108]. Several lines of evidence also suggest that
KRAS oncogenesis predominantly depends on the MAPK pathway: First, KRAS-WT
pancreatic ductal adenocarcinomas (PDACs) have BRAF mutations, which phenocopy
KRAS rather than PI3K pathway mutations [109-111]. Second, PI3K mutations co-occur
with KRAS mutations indicating that KRAS does not potently activate the PI3K/AKT
pathway [112]. Finally, only activated RAF and MEK can restore the growth of RASless
mouse embryonic fibroblasts (MEFs) [113].
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3. KRAS localization and nanoclustering
KRAS signaling occurs predominantly on the PM to where effectors are recruited
and activated. A prerequisite for effector recruitment is the formation of transient (t<1s)
GTP-KRAS nanoclusters, containing 5-6 KRAS proteins which selectively sort PM lipids
[114-117]. Though it has historically been thought that the KRAS polybasic domain (PBD)
associates with anionic PM phospholipids purely through electrostatic interactions,
recent work has shown that the PBD-farnesyl anchor actually exhibits exquisite binding
specificity for PtdSer. Indeed, the precise amino acid sequence of the PBD and the
prenyl group define a cryptic code for lipid binding specificity [115, 117]. Differential
interactions between different lysine side chains and PM lipids lead to a realized tertiary
structure on the PM with a very specific binding preference for PtdSer [118]. Moreover
the KRAS anchor binds specifically to asymmetric PtdSer containing one saturated and
one desaturated tail, thus the anchor also recognizes the acyl chain structure of PtdSer
[119]. In consequence, KRAS PM binding and spatial organization is highly sensitive to
PM PtdSer content such that decreasing levels of endogenous PtdSer decreases KRAS
PM levels, nanoclustering, and signaling [117, 119-121]. A role for G-domain homodimerization in KRAS spatial organization has also been proposed. Dimerization
surfaces have been identified by molecular dynamics (MD) simulations that allow the
building of membrane-bound KRAS oligomers up to and including pentamers [122, 123]
To some extent these surfaces have been validated by mutating interacting residues,
which leads to reduced nanoclustering in intact cells and altered biology in more complex
analyses [122, 123]. What is clear is that dimers involve low affinity protein interactions
and only exist in the constrained two diffusional space of a membrane surface. However,
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the lipid composition of that membrane is also critical; reconstitution experiments with
simple bilayers have failed to visualize any evidence of RAS dimerization or
oligomerization [124], whereas more complex supported bilayers that emulate the lipid
composition of the plasma membrane faithfully recapitulate KRAS nanoclustering
behavior [125]. Similarly, isolated KRAS anchors also display lipid-dependent
nanoclustering behavior. In sum, anchor-lipid interactions are likely the driving force for
KRAS nanoclustering on the PM with additional regulation, or modulation, provided
through G-domain-lipid and G-domain-G-domain interactions. A thorough review of RAS
PM targeting, spatial organization and anchor-induced lipid sorting can be found in [118].
KRAS signaling through the MAPK pathway occurs primarily on the PM, but has
also been reported to occur from intracellular membranes such as the Golgi [27, 37], ER,
endosomes [126, 127] and mitochondria [128, 129]. One method includes KRAS
phosphorylation by PKC which leading to KRAS translocation to the ER, Golgi or to the
mitochondrial outer membrane where it interacts with BcL-XL to promote apoptosis [46,
130]. Furthermore, it’s been demonstrated that different signaling pathways are activated
from different locations: PM-localized RAS could activate Erk, Akt and Jnk; while Golgilocalized RAS activated Erk, Akt and cSrc [131]. The nature of MAPK signaling from
these different platforms also varies. For example, EGFR activation leads to initial RAS
activation on the PM and subsequently on Golgi membranes. RAS activation on the PM
is rapid and transient (1-10 minutes) while activation on the Golgi is delayed and
sustained (>20 minutes) [131]. GTP-KRAS nanoclusters on the PM operate as digital
switches which translate a graded/analog input (RAF kinase activities) into amplified
fixed/digital output (pp-ERK) [116, 132, 133]. In contrast, RAS signaling on the Golgi
generates a graded pp-ERK output, indicating the requirement of a higher activation
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threshold for the MAPK module in the Golgi compared to at the PM [134]. Interestingly,
high-threshold graded Golgi MAPK signaling has clear biological relevance in the context
of thymic deletion of highly autoreactive T-cells during fetal development [135]. The fact
that one signaling module can generate different signaling dynamics and produce
fundamentally different outputs points towards the importance of the nanoscale
heterogeneity present within membrane environments.
4. KRAS Inhibitors
The quest to identify KRAS inhibitors has taken over 30 years, a journey that
earned KRAS an “undruggable” status [136]. The first crystal structure of RAS solved in
1989 showed that, other than the nucleotide binding site, KRAS lacks any deep pockets
that can be susceptible to small molecule binding [112, 137, 138]. Additionally, acquired
drug resistance by many means including mutational changes, upregulation of
compensatory pathways or microenvironment-mediated resistance mechanisms [139]
further amplifies the obstacles that need to be overcome. Many chemical screens have
identified novel compounds that selectively inhibit oncogenic KRAS signaling when
performed in KRAS mutant and wildtype isogenic cell line pairs [140, 141]. However,
translation of these targeted therapies to the clinic has been limited due the inability to
identify the specific protein target of the drug and its ensuing development. Furthermore,
a growing body of evidence has showed that single agent treatment will not be efficacious
in treating KRAS-mutant cancers in the long run due to the prevalence of acquired and
de novo resistance [142]. Nevertheless, many combination therapies and new
approaches to inhibiting KRAS signaling are emerging which can broadly be categorized
into three strategies: (1) Direct inhibition of KRAS by targeting the nucleotide binding
pocket, or allosterically modulating KRAS activity by binding newly identified surface
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pockets, (2) inhibition of downstream effectors of KRAS, and (3) inhibition of KRAS-PM
interactions.

4.1 Direct KRAS Targeting:
4.1.1: Non-nucleotide Site Binding
RAS proteins have a picomolar affinity for GTP, which when combined with the
cellular concentration of GTP in the millimolar range, essentially eliminates the feasibility
of developing of GTP-competitive inhibitors for KRAS [82, 143]. This contrasts with the
relative ease of designing ATP-competitive inhibitors against receptor tyrosine kinases
(RTKs) that have binding affinities for ATP in the low micromolar to millimolar range [144].
Many attempts have been made to engineer proteins that specifically bind KRAS,
including whole antibodies [145], single chain variable fragments [146], affibodies [147],
monobodies [148, 149], DARPins [150], anticalins and other biologics that bind to
allosteric sites on RAS (reviewed in [151]). Allosteric inhibitors targeting RAS
dimerization and protein-protein interactions, rather than nucleotide analogs, seem to
offer a feasible approach to inhibit RAS function [148, 149, 152, 153]. Moving forward,
some degree of isoform and mutant specificity may be required to limit potential toxicity
that may arise from inhibiting all RAS proteins [154]. For example, some pan-RAS
inhibitors disrupt RAS-RAF interaction by binding to sites adjacent to the effector binding
site and have shown promising results in vitro and in vivo; however, concern with toxicity
in normal cells arise when targeting all isoforms [155].
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KRAS allosteric sites were discovered by Gorfe and colleagues through ensemble
docking, MD simulations, bioinformatics, and in vitro validation of potential inhibitors.
They showed that helix 5 and loop 7 are involved in allosteric regulation of the nucleotidebinding switch, and identified three adjacent transient binding pockets, termed p1, p2
and p3 (Figure 2). Virtual screening and ensemble docking were then used to identify
novel small molecule binders to these pockets that could not be captured by traditional
crystallography [156, 157]. Their efforts led to the identification of a novel
pyrazolopyrimidine-based allosteric KRAS inhibitor, compound 11 (Figure 3A), that binds
GTP-KRAS at the “p1”
pocket with an IC50 of
~1-5 μM, disrupting
RAS-RAF
inhibiting

binding,
KRAS

signaling and cancer
cell proliferation [158].
Figure 2. Druggable allosteric pockets on KRAS. Ensemble fragment mapping
analysis identified four allosteric binding pockets, p1, p2, p3 and p4 (pink, green, blue
and yellow, respectively), on the catalytic domain of KRAS. P1 is located near the corebeta sheet while p2 is between helix 3 switch 2. P3 and p4 are near the C-terminus and
behind switch 1, respectively. Image reproduced from Grant et al. with permission [159].
This figure was originally published in Kattan, W. E., Chen, W., Ma, X., Lan, T. H., van
der Hoeven, D., van der Hoeven, R., & Hancock, J. F. (2019). Targeting plasma
membrane phosphatidylserine content to inhibit oncogenic KRAS function. Life Sci
Alliance, 2(5). doi:10.26508/lsa.201900431. Copyright permission granted on 21 May
2021.
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Macromolecule inhibitors bind their targets with high specificity and affinity but
their large size hinders uptake by cells. While small molecule drugs overcome this issue,
their small size means a smaller surface area to bind targets and lower target affinity
[160-162]. To circumvent these issues, Quevedo et al. used intracellular antibody
capturing technology [163, 164] to develop an antibody fragment that binds to all RAS
isoforms in the GTP-bound conformation. They showed that their product bound to RAS
with low Kd, high Kon and low Koff, and inhibited tumor growth in vivo [165]. Since it bound
to RAS with such desirable properties, they used it as a starting point to screen for other
compounds that bound RAS at the same location and discovered a compound, Abd-7,
that bound RAS adjacent to the effector binding region. Treatment with Abd-7 reduced
signaling through the PI3K and MAPK pathways as measured by decreased levels of pAKT and pp-ERK in colorectal and non-small cell lung cancer cell lines. Their work
showed that using intracellular antibody fragments as starting points for drug
development represents a viable option for the generation of small high-affinity
compounds [166].
Another intriguing mechanism visualizes targeting RAS-membrane interaction
sites to lock KRAS in an orientation with respect to the PM that occludes access to the
effector binding site. This was demonstrated by the compound, Cmpd2, discovered using
nanodiscs coupled with NMR spectroscopy to generate and characterize atomic-scale
structures of KRAS on a 20% PtdSer lipid bilayer [167].
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4.1.2: KRAS G21C Inhibitors
Mutant G12C KRAS is found in approximately 13% of non-small cell lung cancer
(NSCLC), 3% of colorectal cancer and 2% of other solid tumors [168]. Many compounds
have been developed to target KRAS G12C following the pioneering work of Shokat and
his group [169] who developed a thiol-reactive compound which binds to a shallow
pocket below switch II and forms a disulfide bond with the mutant cysteine to lock KRAS
in the GDP-bound state [170-174]. One such KRAS G12C inhibitor, ARS-853, was
among the first compounds to show drug-like qualities in potency and selectivity [173].
KRAS G12C has a much faster nucleotide cycling time (t1/2 of nucleotide release = 9.9
minutes, t1/2 hydrolysis = 27 minutes) compared to G12D and G12V mutants (>3 hours)
[175]. Because of this fast-cycling time, such mutants remain sensitive to upstream
signals rendering ARS-853 more effective when coupled with EGFR inhibitors like
erlotinib that increase the cellular fraction of GDP-KRAS. In contrast, combination
treatment with MEK1/2 inhibitors renders ARS-853 treatment less effective due to loss
of negative feedback inhibition of ERK1/2 on SOS1 (a RAS GEF), increasing the amount
of GTP-KRAS that cannot be bound by ARS-853 [173]. These in vitro studies led to the
development of ARS-1620 by structure-based design, a highly potent and selective
KRAS G12C inhibitor that induced tumor regression in vivo [170].
The first-in-human clinical trials with Amgen’s G12C inhibitor AMG 510 are
underway with promising preliminary results in lung cancer patients (clinicaltrials.gov
identifier NCT03600883, phase1/2), but not colorectal cancer patients. Although 47% of
lung cancer patients (11 out of 23) experienced tumor shrinkage, this occurred in only
3% (1 out of 29) of colorectal cancer patients [168, 176, 177]. Clinical trials studying the
effects of combining AMG 510 with MEK or PD1 inhibitors in solid KRAS G12C tumors
(clinicaltrials.gov identifier NCT04185883, phase 1b) and trials comparing AMG510
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treatment versus Docetaxel in NSCLC (clinicaltrials.gov identifier NCT04303780, phase
3) are underway. Oher pharmaceutical companies have also manufactured KRAS G12C
inhibitors that are currently in clinical trials such as Mirati Therapeutics MRTX894
(clinicaltrials.gov identifier NCT03785249, phase1/2) [178].
Recent work elucidated potential resistance mechanisms to AMG 510 in three
models of KRASG12C lung cancer [179]. Single-cell RNAseq revealed that inhibitor
treatment increased p21 and p27 expression levels indicative of a quiescent (G0) state
[180] in 80% of the cell population while the remaining 20% were termed “adapting” cells.
Adapting cells initially undergo growth inhibition upon treatment but this is followed by
accumulation of GTP-KRAS and finally MAPK reactivation, a pattern seen in many cases
of acquired drug resistance [181-183]. A genome-wide knock-out screen revealed that
heparin-binding epidermal growth factor (HBEGF), aurora kinase A (AURKA) and KRAS
were essential for the AMG 510-adapting cell population. Increased HBEGF in adapting
cells led to activated EGFR signaling, which proved essential for escaping the G0 state.
The role of AURKA in mitogenic signaling [184-186] and acquired resistance to PI3K or
EGFR inhibitors has been well established [187, 188]. In this setting, AURKA stabilized
the interaction between GTP-KRAS and CRAF; and co-treatment with AMG 510 and an
AURKA inhibitor inhibited CRAF and ERK activation more extensively than treatment
with either inhibitor alone. Cells expressing higher KRAS levels quickly convert GDPKRAS to GTP-KRAS by increased upstream EGFR signaling and maintain the GTPKRAS-CRAF interaction downstream by AURKA signaling, ultimately leading to cell
cycle progression and escape from G0 [179]. These results likely explain why the
majority of patients in the AMG 510 clinical trial have only had partial responses [176].
BI-2852

(available

at

https://opnme.com/molecules/kras-bi-2852)

targets

KRASG12C via a fundamentally different mechanism from other G12C inhibitors. BI16

2852 binds to a pocket between switch I and switch II (SI/II-pocket), rather than above
switch II (SII-pocket), which is unaffected by KRAS activation status [189]. Therefore, BI2852 blocks interaction of both GDP- and GTP-KRAS with SOS1 [190] as well as GTPKRAS with GAPs [191], CRAF and PI3Ka, inhibiting signaling and proliferation of KRASmutant cells in the low micromolar range [192, 193]. BI-2852 binds to all RAS isoforms
but has a 10-fold increased selectivity for KRAS-G12D compared to KRAS WT [194].
Further optimization to confer isoform and mutant specificity is warranted.
An obvious limitation of KRAS-G12C inhibitors is that they are mutation specific,
and most KRAS-mutant tumors have G12V or G12D mutations that have yet to be
successfully targeted. However, this is a very active area of research [166, 195-197],
with the SI/II pocket garnering most attention.

4.2 Downstream Effector Targeting
The reason many have turned to targeting downstream effectors rather than
KRAS itself is twofold: First, as opposed to ATP-competitive inhibitors commonly used
to inhibit receptor tyrosine kinases (RTKs) that have binding affinities for ATP ranging
from the low micromolar to millimolar range [144], Ras proteins have a picomolar affinity
towards its nucleotide, guanine. In addition to the high binding affinity KRAS has towards
GTP, the cellular concentration of GTP is in the millimolar range, hindering any
nucleotide analog from binding to KRAS [82, 143]. Second, the first crystal structure of
RAS solved in 1989 showed that KRAS lacks any other deep pockets that can be
susceptible to small molecule binding [112, 137, 138]. There have been some attempts
to lock switch I of KRAS in the state 1 conformation which disfavors effector binding. This
was accomplished by the use of transition metal compounds such as Zn-cyclen and Cu-
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cyclen which selectively target the state I conformation and diminish RAS-RAF
interaction [198, 199]. Their use as potential therapies in vivo; however, were
unattainable because of their non-druglike nature [16].
Identifying a suitable therapeutic window for agents that target KRAS or the MAPK
pathway has been difficult as these pathways are essential for regulating cell growth and
survival in normal cells. Efficacy has also been a recurring issue when trying to target
the MAPK pathway, as doses required for efficient inhibition can be toxic [200-202].
Therefore, acquired drug resistance in tumor cells treated with these drugs is inevitable
due to the strong selective pressure on cancer cells, which are inherently genetically
unstable and able to adapt quite quickly. Downstream effector inhibitors have been
extensively reviewed elsewhere [1, 3, 82, 112, 136, 203, 204] and so will only be
considered briefly here to illustrate some mechanisms of resistance.
In the case of BRAF inhibitors for example, resistance is acquired through
increased HGF secretion by stromal cells which activates both the MAPK and PI3K
pathways via MET activation. Concordantly, BRAF-mutant melanoma patient data
showed that those with stromal HGF had a significantly worse treatment response [139].
MET activation may also have a role in mitigating the action of gefitinib, an EGFR
inhibitor, in non-small cell lung cancer [205-209]. HGF-induced resistance is immediate
and innate as opposed to acquired resistance to drugs developed over time, but could
be reduced by a combination of MEK and AKT inhibition [139]. BRAFV600E colorectal
cancer cell lines treated with RAF inhibitors also develop resistance through EGFR
activation [181, 183]. One recurring theme of resistance seen with many BRAF inhibitors
is paradoxical activation of ERK due to alleviation of negative feedback mechanisms
imposed by ERK on upstream components of the pathway [210-213], which is also seen
with MEK1/2 inhibitors [112].
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Rigosertib was developed as a RAS-mimetic that binds the RAS binding domain
(RBD) of RAF [214]. This molecule inhibits RAS signaling but the mechanism of action
remains unclear since Rigosertib binds the RAF-RBD with low affinity and cannot
dissociate RAF from GTP-bound RAS. Rigosertib may induce mitotic stress and the
generation of reactive oxygen species leading to JNK-mediated inhibition of SOS and
RAF, to suppress the MAPK pathway in a KRAS non-specific manner [215].
SHP2 is a tyrosine phosphatase that acts upstream of KRAS to promote MAPK
signaling and also mediates resistance to BRAF or MEK inhibitors in specific ERKdependent tumors [216]. In addition, combination treatment with SHP2 inhibitors also
abrogated the RTK reactivation observed with KRASG12C inhibitors, leading to
sustained MAPK inhibition with better outcomes in vitro and in vivo. Several SHP2
inhibitors are currently under clinical evaluation since SHP2 inhibition has shown efficacy
in RAS-mutant glioblastoma, pancreatic and lung cancers and in gastroesophageal
cancers with WT KRAS amplification (ClinicalTrials.gov Identifiers: NCT03114319;
NCT03565003; NCT03634982) [217-221]. Full details on all clinical trials involving RAS
effector therapies can be found in a recent review [16].
4.3 Synthetic Lethality
Much work has been directed to identifying tumor-specific vulnerabilities that may
be targeted to cause tumor cell death, a phenomenon termed synthetic lethality [222].
Such vulnerabilities may include non-oncogenic metabolic or genetic programs on which
cancer cells have become dependent, so called non-oncogene addiction [223, 224].
Normal cellular processes that become critical for the maintenance of KRAS-mutant
tumors include regulation of oxidative, genotoxic and ER stress, autophagy,
macropinocytosis, glycolysis, and enhanced glutamine uptake in PDAC. Inhibitors of
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these pathways are currently in different stages of preclinical and clinical evaluation
(reviewed in [225]).
For example, inhibiting KRAS function in PDAC cell lines leads to increased
autophagy as a mechanism of cell survival [226-228]. Targeting both the MAPK and
autophagy pathways has synergistic effects in vitro and in vivo in KRAS-mutant PDAC,
NRAS-mutant melanoma and BRAF-mutant colorectal cancer. Moreover, co-inhibition of
MEK and autophagy using trametinib and hydroxychloroquine, respectively, in a single
PDAC patient led to significant reduction in levels of CA19-9 tumor marker, overall tumor
burden and cancer-associated pain [227].
KRAS G12R tumors exhibit a selective vulnerability to inhibitors of PI3K and
macropinocytosis. Though quite rare in other cancers (~1% in NSCLC and CRC), G12R
mutations comprise up to ~20% of KRAS mutations in PDAC. KRAS G12V and KRAS
G12D expression stimulate macropinocytosis while KRAS G12R lacks this ability. The
G12R substitution causes a structural change in switch II that impairs binding to the PI3K
p110a subunit and hence activation of PI3K/AKT signaling, which is essential for
macropinocytosis. KRAS-independent upregulation of PI3Kg signaling is therefore
required to support macropinocytosis in KRAS G12R-PDAC. In consequence, KRAS
G12R-PDAC is more sensitive than G12D-PDAC and G12V-PDAC to ERK/MAPK and
autophagy inhibition. Interestingly, simultaneously targeting both pathways was
synergistic in G12D- and G12V-PDAC but additive in G12R-PDAC [229].
A genome-wide synthetic lethal RNAi screen in RAS-mutant tumors yielded
multiple hits in the mitotic stress response pathway, including subunits of the APC/C
complex and the mitotic kinase PLK1 [142]. Concordantly, mutant RAS positive lung
cancer patients had increased overall survival if APC/C levels were low, whereas APC/C
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activity level had no prognostic bearing in mutant RAS negative patients. PLK1 is
activated at the G2/M transition by Aurora A Kinase leading to mitotic progression.
Activated KRAS may lead to oncogene-induced senescence and so KRAS-mutant cells
seem to have a higher dependence on PLK1 to progress through mitosis, as evidenced
by increased levels of total and activated (phospho-)PLK1 [142]. This compensatory
mechanism was also seen with KRAS G12C inhibitor-resistant cells, which had
increased Aurora A Kinase levels [179]. In this context the PLK1 inhibitor, BI-2536
significantly inhibited the growth of KRAS transformed HCT116 and DLD-1 colorectal
cancer cell xenografts. Other pathways essential for RAS-mutant cell growth include
ribosomal biogenesis, RNA splicing and mRNA translation, and posttranslational
modifications such as neddylation and sumoylation [142]. An extensive list of RAS
synthetic lethal functional genetic screens can be found in [225]. Unfortunately many of
the early hits from these studies could not be validated or recapitulated
pharmacologically [75, 142, 230], and to date none have advanced to the clinic for the
treatment of mutant RAS cancers [231].
4.4 Inhibiting KRAS Posttranslational Modification and Plasma Membrane Recycling
A valid mechanism to inhibit KRAS function is to block PM localization [232]. As
discussed previously, KRAS requires the posttranslational attachment of a membrane
anchor to localize to the PM. The first step in this process can be blocked by Farnesyl
Transferase inhibitors (FTIs). Highly potent and relatively non-toxic FTIs were developed
in the early 1990s that blocked the growth of HRAS mutant tumors in mouse models
[233-236]. Concordantly, an ongoing phase 2 clinical trial conducted by Kura Oncology
for the FTI tipifarnib in patients with HRAS-mutant relapsed or refractory urothelial
carcinomas has seen promising results: 5 of the 13 patients treated achieved objective
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responses and 4 experienced progression-free survival greater than 6 months
(clinicaltrials.gov identifier NCT02535650) [237]. Kura oncology is conducting another
phase 2 tipifarnib clinical trial in HRAS-mutant Head and Neck Squamous Cell
Carcinoma (clinicaltrials.gov identifier NCT02383927) and have reported a 56% overall
response rate with progression free survivals of 6.1 months compared to 2.1 months on
previous therapies [238]. However, FTIs did not provide such promising results in earlier
trials with KRAS-mutant tumors because in FTI-treated cells, KRAS and NRAS are
alternatively prenylated by geranylgeranyltransferase I (GGTaseI) allowing normal PM
localization [3, 239-243]. Attempts to circumvent this escape mechanism to date have
been unsuccessful. A GTTase1 inhibitor (GGT1-2418) that was well tolerated in phase
1 studies had limited efficacy (https://drugs.ncats.io/drug/ M67G28K74K) [16], and
combining FTIs with GTTase1 inhibitors (GGTIs), whilst showing promising efficacy in
inhibiting prenylation of all RAS isoforms in preclinical experiments, proved to be too
cytotoxic, with a therapeutic index too low to be implemented as a treatment option [244,
245]. Probably because together, FTase and GGTase1 prenylate a large number of
proteins important for normal cellular growth and function [246]. One dual
prenyltransferase inhibitor, “L-778,123” that advanced to two different phase 1 clinical
trials failed to inhibit KRAS prenylation [247, 248] despite some apparent efficacy in vitro
[249].
A second approach to prevent PM KRAS localization involves blocking the
function of PDEδ, which as reviewed above promotes recycling of cytosolic KRAS to
maintain the fidelity of PM targeting [47, 49]. Inhibiting PDEδ leads to the accumulation
of KRAS on endomembranes, where it cannot signal. An early small molecule PDEδ
inhibitor, Deltarasin, bound to the prenyl-binding pocket of PDEδ with nanomolar affinity
and inhibited KRAS signaling in in vitro PDAC models but its effective in vivo dose was
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in the micromolar range and caused off-target cytotoxicity that limited efficacy [250]. A
second generation PDEδ inhibitor, Deltazinone 1, to some extent circumvented these
problems and was efficacious against PDAC [251]. Other compounds, such as
Deltasonamide 1 and 2 also inhibit KRAS-mutant colorectal cancer cell proliferation but
suffer from low membrane permeability [252, 253].

4.5 Inhibiting KRAS Plasma Membrane Localization
An unbiased high content screen with a library of 1,120 FDA-approved small
molecules was used to identify inhibitors of KRAS PM localization [254]. Some hits, also
identified previously, included weak amphiphilic bases which only caused moderate
dissociation of KRAS from the PM [255], but the top hit, fendiline, significantly
mislocalized KRAS (IC50 =3.14 µM) as well as the PtdSer (IC50 =3.16 µM) from the PM
in a dose-dependent manner. Importantly, fendiline had no effect on NRAS or HRAS
localization or on CAAX processing [254, 256].
Fendiline is an L-type voltage-gated Ca2+ channel blocker originally used to treat
angina [257]. Other Ca2+ channel blockers had no effect on KRAS, indicating a new
function unrelated to Ca2+ channel activity and unrelated to changes in intracellular Ca2+
levels [254, 258]. Fendiline is a racemic compound; however, only the R-fendiline
stereoisomer (hereafter fendiline, Figure 3B) significantly mislocalized KRAS. Fendiline
treatment abolished KRAS-dependent MAPK and PI3K signaling at concentrations
similar to those required for KRAS mislocalization, and more potently inhibited
proliferation of KRAS-mutant cells in a panel of 21 pancreatic, lung, colorectal and
endometrial cancer cell lines [254]. This selectivity was also observed in vivo in xenograft
mouse models of KRAS-mutant or KRAS-WT pancreatic tumors with no observed
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organismal

toxicity

[259].

Because

fendiline reduced KRAS PM levels and
inhibited both the MAPK and PI3K/AKT
pathways, it may have potential use as
an

adjuvant

therapy

with

kinase

inhibitors that lead to paradoxical reactivation of these pathways; such as
mTOR and BRAF inhibitors that activate MAPK signaling [260, 261]. Fendiline
derivatives have been synthesized that show increased potency in terms of KRAS
mislocalization, inhibition of cell proliferation in vitro and tumor growth in vivo [262].
Figure 3. Chemical structures of several KRAS signaling inhibitors. (A) Compound
11 binds to the p1 allosteric pocket on KRAS to inhibit its function; image reused with
permission

from

McCarthy

(https://pubs.acs.org/doi/10.1021/acsomega.8b03308).

et
(B)

al.
Fendiline

[158]
inhibits

acid

sphingomyelinase in the lysosome, resulting in PtdSer and KRAS mislocalization from
the PM. (C) G01 inhibits acid sphingomyelinase as well but also perturbs RAS recycling
to the PM through the recycling endosome pathway by inhibiting APEH; republished with
the permission of ASBMB, from “An oxanthroquinone derivative that disrupts RAS
plasma membrane localization inhibits cancer cell growth”, Tan et al., vol. 293, issue 35,
2018; permission conveyed through Copyright Clearance Center, Inc. [263]. (D) C7
selectively inhibits PI4KIIIα leading to depletion of PI4P from the PM and concomitant
mislocalizaion of PtdSer and KRAS; image reused from Raubo et al. with permission
from Royal Society of Chemistry [264]. This figure was originally published in Kattan, W.
E., Chen, W., Ma, X., Lan, T. H., van der Hoeven, D., van der Hoeven, R., & Hancock,
J. F. (2019). Targeting plasma membrane phosphatidylserine content to inhibit
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oncogenic KRAS function. Life Sci Alliance, 2(5). doi:10.26508/lsa.201900431.
Copyright permission granted on 21 May 2021.

Fendiline operates as an indirect inhibitor of lysosomal acid sphingomyelinase
(ASM) which converts sphingomyelin (SM) to ceramide (Cer), leading to SM
accumulation in the lysosome [259, 265, 266]. Fendiline treatment reduces PM
cholesterol levels, increases PM SM levels, and decreases PM PtdSer and cellular
ceramide levels. Concordantly, since KRAS PM localization and nanoclustering depends
on PM PtdSer levels, supplementation with exogenous PtdSer rescued fendiline-induced
KRAS mislocalization and MAPK signaling [256]. ASM facilitates NPC2-mdiated
cholesterol efflux from the lysosome in part explaining the decreased cholesterol content
seen in the PM of fendiline-treated cells [259]. More broadly, SM accumulation
destabilizes lysosomal membranes [267] and impedes membrane fusion events such as
those occurring during autophagy [268].
Fendiline and other ASM inhibitors, such as siramesine and cationic amphiphilic
drugs (CADs), are concentrated in the lysosome where they interfere with the binding of
ASM to bis-monoacyl-glycerophosphate (BMP) on the inner lysosomal membrane [269].
Displacement of ASM from BMP results in relocation to the lysosomal lumen where it
undergoes degradation [270]. Siramesine and other CADs such as desipramine and
amlodipine selectively kill KRAS-mutant HCT116 colon cancer cells but not the KRASWT isogenic line [269]. Cancer cells generally have destabilized lysosomes due to
elevated proteolytic activity and dependency on autophagy [271] and siramesine has
been shown to effectively inhibit autophagic flux [272, 273]; other clinically relevant CADs
probably have the same effect. The additional effect of fendiline on KRAS PM localization
would add loss of KRAS signaling to these detrimental shared effects on lysosomal
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function, perhaps accounting for the increased sensitivity of KRAS-mutant cancer cells
to fendiline treatment [274, 275].
Three FDA-approved tricyclic antidepressants, desipramine, imipramine and
amitriptyline, which also inhibit ASM, [265, 276] mislocalize KRAS and PtdSer at similar
IC50 values in a dose-dependent manner and significantly decrease KRAS
nanoclustering on the PM. These effects were translated to decreased MAPK signaling
and preferential inhibition of KRAS-mutant pancreatic, colon, lung and endometrial
cancer cells over KRAS-WT cells. ASM inhibitors also block mutant let-60 (KRAS
homolog) signaling in C. elegans [259].
Sphingomyelin is generated by de novo synthesis from serine and palmitate by
serine palmitoyl transferase (SPT) [277, 278], or by addition of a choline head group from
phosphocholine to ceramide by sphingomyelin synthases (SMases) [279, 280]. Several
targetable components of SM metabolism that decrease KRAS function were identified
by an RNA interference screen against 18 enzymes of the Cer-SM biosynthetic pathway
in the C. elegans system. Among the identified genes whose inhibition most potently
suppressed let-60 signaling (~70%) were sphk-1 (sphingosine kinase 1), hyl-2 (ceramide
synthase) and, unsurprisingly, asm-1 which encodes acid sphingomyelinase [259].
SPHK1 is a kinase that phosphorylates sphingosine to sphingosine-1-phosphate (S1P),
an extensively-studied active oncometabolite that promotes cell proliferation and survival
[281, 282].
Validation of hits with pharmacological inhibitors in mammalian cells revealed that
inhibition of ceramide synthase with fumonisin B1, dihydroceramide desaturase with
GT11, or ceramide kinase with K1 potently misloclaized PM KRAS and PtdSer. These
enzymes function in the Cer-SM de novo biosynthetic pathway and their inhibition in vitro
significantly perturbed cellular SM levels or SM distribution and depleted PM PtdSer.
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Fumonisin B1, GT11 and K1 concordantly dose-dependently mislocalized KRAS from
the PM at concentrations similar to those needed to inhibit their enzyme targets [259].
Additionally, inhibiting ORMDL3, a negative regulator of SPT, by very low concentrations
of staurosporine (STS) [256] increased SM content by de novo synthesis [283].
G01 (3-O-methyl oxanthroquinone ethyl ester) is a derivative of oxanthroquinone,
a polyketide structure discovered from a high content screen for inhibitors of KRAS PM
binding (Figure 3C) [284]. G01 is an inhibitor of acylpeptide hydrolase (APEH), a prolyloligopeptidase that removes Nα-acylated amino acids from peptides and functions in
protein degradation of oxidized and glycated proteins [285-291]. G01 treatment
significantly inhibited the PM localization and nanoclustering of HRAS, KRAS4B (KRAS),
KRAS4A and PtdSer with an IC50 of ~ 1μM [263, 285]. Further analysis suggests that
this effect of G01 on multiple RAS isoforms [263] reflected a disruption of RE function
which is crucial for maintaining RAS PM localization [49, 292]. The importance of the RE
in maintaining RAS on the PM is echoed by studies showing that thioesterase inhibitors
which prevent HRAS and NRAS depalmitoylation [293, 294], PDEδ inhibitors or RAB11
knockdown which prevent KRAS loading on to the RE [49, 250, 295] all lead to their
redistribution to endomembranes. Similarly, a commercially available APEH inhibitor
called ebelactone A inhibited APEH function at concentrations similar to that required to
mislocalize KRAS from the PM [285, 290, 296]. Interestingly, in a cohort of patients
encompassing 33 different types of cancer, APEH was expressed at significantly higher
levels in KRAS-mutant as opposed to KRAS-WT tumors [285]. Precisely how APEH
inhibition impairs RE function remains unclear, but may be related to aberrant
proteasomal regulation [285].
G01 blocks MAPK signaling in cells expressing constitutively active KRAS or
HRAS at the same concentrations that cause mislocalization from the PM. This
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translated to decreased proliferation of a panel of 14 cell lines comprising pancreatic,
colon, endometrial and lung cancer lines when treated with G01. Interestingly, cell lines
harboring mutant KRAS were more sensitive to treatment than cell lines expressing WT
KRAS in all but the lung cancer cell lines [263]. G01 also inhibited ASM and NSM, leading
to elevated SM and cholesterol content [285] as seen with fendiline and fumonisin B1
[256, 259].
One unifying feature of these different mechanisms of lipid homeostasis is that
they indirectly regulate PM PtdSer levels. Thus, their disruption decreases PM PtdSer
content, and hence the capacity of KRAS to stably localize to and nanocluster on the
PM. These observations in turn suggest that other approaches to disrupt PtdSer PM
localization will also abrogate KRAS function.
4.5.1 Phosphatidylserine and KRAS Function
PtdSer accounts for 4-6% of total cellular lipids [297-299] but is the major anionic
lipid species of the inner leaflet of the PM, accounting for ~25mol% [4, 300]. PtdSer is
synthesized on the cytosolic leaflet of the ER by PtdSer synthase-1 (PSS1) and PtdSer
synthase-2 (PSS2) [301] which, respectively, replace the choline or ethanolamine
headgroups of phosphatidylcholine (PC) or phosphatidylethanolamine (PE) with serine
[302-304]. Deletion of both PSS isoforms is lethal [305]; whereas cells with a nonfunctional PSS1 are viable [306-308]. From the ER, PtdSer is transported to
mitochondria, PM, endosomes, lysosomes, and the trans-Golgi network by lipid transport
proteins (LTPs) or vesicular transport [309-312]. Among intracellular organelles, PtdSer
is most enriched in recycling endosomes (REs) [313]. PtdSer binding proteins such as
evectin-2 mediate retrograde trafficking between the RE and Golgi and likely contribute
to the maintenance of high PtdSer levels on the PM [302, 313, 314].
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PtdSer is mainly transported from the ER to the PM by Oxysterol Related Binding
Protein 5 and 8 (ORP5 and ORP8) encoded by OSBPL5 and OSBPL8, respectively
[315]. ORP5 and ORP8 share 80% sequence identity [316] and are ER-resident proteins
that function as lipid exchangers at membrane contact sites (MCSs) between the ER and
PM, or mitochondrial outer membrane [317, 318]. MCSs are microdomains where two
organelle membranes are arrayed within 10-30 nm of each other to facilitate molecule
exchange [319]. At ER-PM MCSs, ORP5 and ORP8 couple PtdSer transport against its
concentration gradient with PI4P transport down its concentration gradient. Dedicated
modes of lipid transport between membranes generate membrane asymmetry which is
then maintained by a variety of “trapping” mechanisms including asymmetric breakdown
and synthesis. In the case of PI4P, it is synthesized on the PM by PM-localized PI4KIIIα
and degraded immediately after transport to the ER by the ER-resident phosphatase
Sac1 phosphatase (Figure 4) [318-321].
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Figure 4. ORP5 and ORP8 transport PtdSer to the plasma membrane in exchange
for PI4P. (A) ORP5 and ORP8 are lipid exchangers that transport PtdSer from the ER
to the PM where they then bind to and transport PI4P to the ER. PI4P is immediately
hydrolyzed to phosphoinositide (PI) by ER-resident SAC1P creating a PI4P
concentration gradient that drives the counter transport process. PM PtdSer molecules
are critical structural elements of KRAS nanoclusters that act as signaling platforms to
activate many pathways, most importantly the RAF-MEK-ERK and PI3K-AKT-mTORC1
pathway which promote cell proliferation and survival. On the PM, PIP5K phosphorylates
PI4P to PI(4,5)P2 which can subsequently be phosphorylated to PI(3,4,5)P3 by PI3K
leading to the activation of the AKT pathway. ORP5/8: Oxysterol Related Binding Protein
5 and 8; SAC1P: SAC1 Like Phosphatidylinositide Phosphatase; PM, plasma
membrane;

ER,

endoplasmic

reticulum;

PtdSer,

phosphatidylserine;

PI4P,

phosphatidylinositol 4-phosphate; PI(4,5)P2, phosphatidylinositol-4,5-bisphosphate;
PI(3,4,5)P3, phosphatidylinositol-3,4,5-trisphosphate; PI4KIIIA, Phosphatidylinositol 4kinase III alpha; PIP5K1B, phosphatidylinositol-4-phosphate 5-kinase type 1 Beta; RAF,
Rapidly Accelerated Fibrosarcoma; MEK, mitogen-activated protein kinase kinase; ERK,
extracellular-signal-regulated kinase; PI3K, phosphoinositide 3-kinase; AKT, also known
as protein kinase B (PKB); mTORC1, mammalian target of rapamycin complex 1. This
figure was originally published in Kattan, W. E., Chen, W., Ma, X., Lan, T. H., van der
Hoeven, D., van der Hoeven, R., & Hancock, J. F. (2019). Targeting plasma membrane
phosphatidylserine content to inhibit oncogenic KRAS function. Life Sci Alliance, 2(5).
doi:10.26508/lsa.201900431. Copyright permission granted on 21 May 2021.

PI4-kinases function mainly at the PM and Golgi to phosphorylate PI at position
D4 of the inositol head group to synthesize PI4P, the precursor of PI(4,5)P2 (PIP2) and
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PI(3,4,5)P3 (PIP3) which are involved in phospholipase C (PLC) and PI3K/AKT signaling,
respectively [322, 323]. There are three classes of PI4-kinases (PI4KI, PI4KII, PI4KIII)
defined by sequence similarity and biochemical properties, each of which contain an α
and a b isoform [322, 324]. The key isoform essential for PtdSer transport to the PM is
PI4KIIIα which is recruited to the PM by a multiprotein complex containing the TTC7
scaffold protein and EFR3A, a palmitoylated protein that tethers the complex to the PM
[324, 325].
Once at the PM, PtdSer is actively concentrated in the inner leaflet by ATPdependent aminophospholipid flippases of the P4 subfamily of P-type ATPases [326330]. In the PM, PtdSer has a multitude of functions involved in coagulation, signaling
cascades, protein recruitment, phagocytosis and the apoptotic response [303, 331-334].
There are two pools of PtdSer, a reactive mobile pool and an immobile pool constrained
by interactions with cortical actin [121, 299].
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CHAPTER 2: MATERIALS AND METHODS
Some of this chapter is based upon:
Kattan, W. E., Chen, W., Ma, X., Lan, T. H., van der Hoeven, D., van der Hoeven,
R., & Hancock, J. F. (2019). Targeting plasma membrane phosphatidylserine content
to inhibit oncogenic KRAS function. Life Sci Alliance, 2(5).
doi:10.26508/lsa.201900431. Copyright permission granted on 21 May 2021.

Materials
Class III PI4K alpha inhibitor Small Molecule (Tool Compound), C7, was
purchased from Cancer Research UK (ximbio.com, cat. no. 153579, distributed by
Ximbio) and dissolved in DMSO. Simeprevir was purchased from MedChem Express (Cat
No. HY-114277). Trametinib, Copanlisib, and LY3214996 were generously provided by
Dr. Scott Kopetz at MD Anderson Cancer Center, Houston, TX. For in vitro experiments,
Simeprevir, Trametinib and LY3214996 were dissolved in DMSO, and Copanlisib was
dissolved in 1M HCL. For in vivo experiments, Simeprevir (SelleckChem, cat# TMC435350), Trametinib (SelleckChem, cat# GSK1120212), and Copanlisib (MedChem
Express, cat# BAY 80-6946) were purchased. Cell culture media were purchased from
HyClone and GIBCO. FBS was purchased from GIBCO. Puromycin was purchased from
Thermo

Fisher

Scientific

(BP2956-100).

Anti-phospho-p44/42

MAPK

(ERK1/2)

Thr202/Tyr204 (43702), total ERK1/2 (4659S), p-c-Raf (9427S), phospho-Ser473 AKT
(4060L), phospho-Thr308 AKT (9257S) pan-AKT (2920S), phospho-EGFR (4407L), GFP
(2956S), β-Actin (A1978), Ki67 (12202) and cleaved caspase 3 (9661 antibodies were
purchased from Cell Signaling Technology. Anti-osbpl5 (NB100-57071) and YAP-1
(NB110-58358) antibodies were purchased from Novus. Anti-osbpl8 (ab99069) antibody
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was purchased from Abcam. Normal rat IgG (sc-2026) was purchased from SantaCruz
Biotechnology. Rabbit anti-mGFP antibodies for immunogold labeling were generated in
house. Agarose-low melting point (CAS 39346-81-1) was purchased from Sigma-Aldrich.

Cell lines
MDCK, HPNE, MiaPaCa-2 and PANC-1 cells were purchased from American
Type Culture Collection. TLA293T cells were a generous gift from Dr. Guangwei Du,
McGovern Medical School, Houston, TX. BxPC3 and MOH were kindly provided by Dr.
Craig Logsdon at MD Anderson Cancer, Houston, TX. KRAS (+/−) HCT116 isogenic cell
line pair was kindly provided by Dr. Scott Kopetz at MD Anderson Cancer Center,
Houston, TX. KPC cells were generously provided by Dr. Jennifer Bailey, McGovern
Medical School, Houston, TX. HEK-HT cells were provided by Dr. Christopher Counter at
Duke University, Durham, NC. MDCK, PANC-1, KPC, HEK-HT and TLA293T cells were
grown in DMEM supplemented with 2 mM L-glutamine and 10% FBS. HPNE cells were
cultured in 75% DMEM and 25% Medium M3 Base supplemented with 5% FBS, 10 ng/ml
human recombinant EGF, 5.5 mM D-glucose, and 750 ng/ml puromycin. MiaPaCa-2 cells
were cultured in DMEM supplemented with 2 mM L-glutamine and 10% FBS and 2.5%
horse serum. BxPC3 and MOH cells were cultured in RPMI-1640 medium supplemented
with 2 mM L-glutamine and 10% FBS. HCT116 cells were cultured in RPMI 1640 including
2 mM L-glutamine and 25 mM sodium bicarbonate, supplemented with 10% FBS. All cell
lines were grown at 37°C in 5% CO2.
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Western blotting
Cells were washed in cold PBS and lysed in buffer containing 50 mM Tris-Cl (pH
7.5), 75 mM NaCl, 25 mM NaF, 5 mM MgCl2, 5 mM EGTA, 1 mM dithiothreitol, 100 μM
NaVO4, and 1% NP40, in addition to protease inhibitors. Whole cell lysates (20 μg) were
immunoblotted and signals were detected with enhanced chemilumisescence (Thermo
Fisher Scientific) and quantified in a LumiImager (Roche Molecular Biochemicals).

Identification of OSBPL5 and OSBPL8 homologs/orthologs in C. elegans
FASTA sequences for human OSBPL5 and OSBPL8 were obtained from the
NCBI

protein

database.

Subsequently,

using

the

blast

tool

in

WormBase

(https://wormbase.org/tools/blast_blat), homologs/orthologs of OSBPL5 and OSBPL8
were identified. Hits with a percentage identity of 30 and above were considered as
candidate genes.

C. elegans strains and growth conditions
C. elegans strain MT2124 was used in the study. The genotype let-60(n1046) IV
of this strain expresses a multivulval (Muv) phenotype in the worms. The worms were
grown at 20oC on Nematode Growth Medium (NGM) plates (2.5 g of peptone, 3 g of NaCl,
20g Agar, 25 mL of 1 M potassium phosphate buffer (pH = 6.0), 1 mL of 1 M MgSO4, 1
mL of 1 M CaCl2, 1 mL of (5 mg/mL in 95% ethanol) cholesterol, 1 mL of (10% v/w in
ethanol) nystatin, and 1 mL of 25 mg/mL streptomycin) containing E. coli OP50.
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Preparation of a synchronous C. elegans culture
Using a sterile worm pick 10 -12 gravid adult worms were transferred from a
previously established plate to newly seeded NGM plates containing E. coli OP50. Plates
were incubated at 20OC overnight. Subsequently, the adult worms were removed using a
sterile worm pick and the embryos were allowed to develop to gravid adult worms (~ 3
days). When the worms reached the gravid adult stage, 4 - 6 plates containing adult
worms were washed with sterile M9W (]5 g of NaCl, 6 g of Na2HPO4, 3 g of KH2PO4 and
1 mL of 1 M MgSO4). The worms were collected in 15 ml conical tubes and centrifuged at
1500 rpm for 1 minute. The supernatant was replaced with worm lysis solution (400 μl of
8.25% sodium hypochlorite and 100 μl of 5 N NaOH). The worms were allowed to lyse to
release the embryos by periodically flicking the tube. The reaction was stopped when 70%
of the adult worms lysed by diluting the medium with M9W. Subsequently, the tubes were
centrifuged at 1500 rpm for 1 minute and the supernatant decanted. The embryos were
washed 3 times with M9W and were resuspend in 3 – 5 ml of M9W. The embryos were
incubated overnight at a speed of 18 rpm on a tube rotator at room temperature (RT). The
resulting L1 larvae were used in the drug assay.

Preparation C. elegans of drug assays
E. coli OP50 was grown in an orbital shaker at 150 rpm and 37oC overnight and
thereafter centrifuged at 4000 rpms for 10 to pellet the cells. The supernatant was
removed, and the pellet was resuspended in 3 ml of M9W to concentrate the culture. Prior
to preparing the drug working solutions, 50 ml of M9W was supplement with 0.05 ml of
cholesterol (5 mg/mL in 95% ethanol). The working solution for each drug was prepared
to a final volume of 4.8 ml M9W supplemented with cholesterol. Thereafter, 200 ml of
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concentrated E. coli OP50 was added to each drug working solution and the vehicle
control. 2 mL of each working drug solution or vehicle control was added to the wells in a
12-well tissue culture plate. Approximately 100 L1 larvae contained in 20ml was added to
each well using a sterile micropipette. The plates were incubated at 20oC. The drug
concentrations and vehicle control were tested in duplicates.

Observation of the Muv phenotype in the let-60 strain
When the worms reached the adult stage, they were collected and washed two
times with M9W. Thereafter, the supernatant was removed without disturbing the pellet
and 500 ml of 2 mM sodium azide was added to anesthetize the worms. 10ml of
anesthetized worm suspension was added to glass slides containing agarose pads. A no.
1.5 coverslip was gently placed over the worm suspension. The samples were imaged
using a DIC microscope at 10X and 20X magnifications. The adult worms were scored
based on the presence or absence of the Muv phenotype.

C. elegans RNAi assay
RNAi-mediated knockdown of osbpl5 and osbpl8 was induced by feeding let60(n1046) worms with Escherichia coli HT115 generating dsRNA to target genes from
their L1 stage to adult stage. A DIC (Differential Interface Contrast)/Nomarski microscope
was used to score the MUV phenotype.

Lentiviral transduction
For lentivirus production, TLA293T cells were transfected with ViraPower lentiviral
packaging mix (K4975-00) using Lipofectamine (18324-012) and PLUS Reagent (10964-
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021). All reagents were purchased from Invitrogen. Lentiviral particles were collected 48
and 72 h after transfection, and then concentrated with Lenti-X concentrator (931232;
Clontech). Titers were estimated with Lenti-X Go-Stix (#631244; Clontech).

Generation of shRNA knockdown cell lines and bicistronic transient infection
OSBPL5 shRNA was purchased from Sigma-Aldrich (cat. no. SHCLNGNM_020896,

shRNAa:

NM_020896.2-1316s1c1:

3′-

CCGGGAACAAGCTCTCCGACTACTACTCGAGTAGTAGTCGGAGAGCTTGTTCTTTT
TTG-5′,

shRNAb:

NM_020896.2-2980s1c1:

3′-

CCGGGCCTTAATGCTAAAGCCAAATCTCGAGATTTGGCTTTAGCATTAAGGCTTTTT
TG-5′,

and

shRNAc:

NM_020896.2-2732s1c1:

3′-

CCGGGTTCATTAACCACATCCTCAACTCGAGTTGAGGATGTGGTTAATGAACTTTTT
TG-5′). shRNA constructs for OSBPL5 were cloned into pLenti6.3-V5-TOPO vector
(K5315-20; Invitrogen). OSBPL8 shRNA pre-packaged into transduction particles was
purchased

from

Dharmacon

(cat.

no.

V3SH7602-226843976:

3′-

TGACAAGCCTATAAACACC-5′). The empty pLKO.1-TRC cloning vector was a gift from
David Root (plasmid #10878; Addgene). GFP-KG12V/mCherry-CAAX and GFPLactC2/mCherry-CAAX bicistronic plasmids were generated in-house and packaged into
lentiviral particles. Pancreatic cancer cells were seeded at 4 × 105 cells per well in sixwell plates, infected with lentiviral particles 24 h later at 70% confluency, and osbpl5 and
osbpl8 knockdown stable cell lines of were selected for with puromycin (4 μg/mL).
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Luciferase Assay
KPC cells were seeded in a 6-well plate and The Dual-Luciferase Reporter Assay
System (Promega, cat# E1910) was used to generate cells constitutively expressing
Luciferase. Luciferase-expressing plasmid was generously provided to us by Dr. Jeffrey
Chang at McGovern Medical School, Houston TX. Single colonies were then selected for
by 250ug/uL Hygromycin B (Invitrogen, PN 10687-010) and luminescence intensity was
measured using a Tecan Infinite M200 Pro microplate reader.

Generation of CRISPR/Cas9 cell lines
CaCO-2

cells

were

transduced

with

human

OSBPL8

sgRNA

(3′-

TGCAAATCTTTGGTTGGCGT-5′) cloned into pLenti6.3-V5-TOPO vector (K5315-20;
Invitrogen) and packaged into viral particles. 24 hours after infection, cells were selected
by 4μg/ml puromycin (BP2956-100, Fisher Scientific) 3 cell passages. Single colonies
were generated from the pool of polyclonal KO cells. KPC cells were similarly infected
with

mouse

OSBPL5

sgRNA

(F:

AAACTGGTCGTTGGAGAGGTACATC)
CACCGCTGAGGCAGATCTCTAGTTG,

CACCGATGTACCTCTCCAACGACCA,

R:

and

(F:

mouse

OSBPL8

sgRNA

R:

AAACCAACTAGAGATCTGCCTCAGCGGTGC) followed by puromycin selection (4
μg/ml) after 24 h for 2 days only to avoid integration of the lentiviral plasmid into the host
DNA to prevent an immunogenic response in animals. Single colonies were chosen, their
DNA extracted and amplified by PCR (OSBPL5 F: ATTCTGGGACCCCTGCTTT, R:
AATATGTGGGTCATGGAGTGC; OSBPL8 F: TCATCGAAAAGGCACATTAGG, R:
AGGCAGAAATGCAATGTGG) using the MangoMix PCR kit (Bioline, cat# BIO-25033)
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which was a generous gift from Dr. Guangwei Du at McGovern Medical School, and
sequenced by Sanger sequencing to verify gene knockout.

RT-PCR
Whole cell RNA was extracted using RNeasy purification kit following the
manufacturer’s instructions (Qiagen, Germantown, MD). Each RNA (500ng /sample) was
converted to cDNA using SuperScriptII (108064-014, Invitrogen) per the manufacturer’s
instructions

followed

by

PCR

amplification

of

mouse

OSBPL5

(F:

CTCTTCTGGACTCCGAGTGA, R: CTTCCATGGAGTGAGGCTCT), mouse OSBPL8 (F:
CTGGAATCCAACTCCTGACA, R: CCAGTGTGGGTCAAGTTC) and mouse B-actin (F:
GCACCAAGGTGTGATGGTG, R: GGATGCCACAGGATTCCATA). Relative expression
was detected by the C1000 Touch Thermal Cycler (Bio-Rad).

Confocal microscopy
Cells were seeded onto coverslips and allowed to grow for 48 h before fixation
with 4% PFA and quenching with 50 mM NH4Cl. Coverslips were then mounted in Mowiol
and visualized by confocal microscopy (Nikon A1R) using a 60X objective.

EM and spatial mapping
Basal PM sheets of CaCO-2, MDCK, HEK-HT and 293T cells were prepared, fixed
with 4% PFA and 0.1% glutaraldehyde, and labeled with affinity-purified anti-GFP antisera
conjugated to 4.5-nm gold as described previously [335]. For 293T cells, cells were
seeded on fibronectin-coated plates. Digital images of immunolabeled membrane sheets
were taken with a transition electron microscope at 100,000× magnification and intact 1-
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μm2 areas were identified with ImageJ. (x, y) coordinates of the gold particles were
determined as described in [335]. Univariate K function [336] was calculated and
standardized on a 99% confidence interval [115, 335, 337], whereby an L(r)-r value
greater than the confidence interval is indicative of significant clustering. The extent of
clustering is represented by the (Lmax) value, the maximum value of the K function.
Bootstrap tests were used to analyze differences between replicated point patterns as
described previously [337], and statistical significance was determined by evaluation
against 1,000 bootstrap samples.

Spatial distribution and clustering of KRAS by electron microscopy
Univariate K-Function Analysis for analyzing the distribution of one species on the
plasma membrane.

Basal PM sheets of CaCO-2, MDCK and HEK-HT cells were

prepared, fixed with 4% paraformaldehyde, 0.1% glutaraldehyde, and labeled with 4.5nm gold directly conjugated to anti-GFP antibody. Images were obtained with a
transmission electron microscope at 100,000x magnification and intact 1μm2 areas were
identified with ImageJ. Univariate K function analysis was performed exactly as described
previously [115, 335, 337]. Bootstrap tests were used to examine for statistical differences
between replicated point patterns and statistical significance was evaluated against 1000
bootstrap samples.
Bivariate K-Function Analysis to quantify the extent of co-clustering between two
different species on the plasma membrane. 293T cells were seeded onto fibronectincoated cover slips. 24 hours later the cells were transiently co-transfected with mGFPand mCherry- or mRFP-tagged proteins of interest. After 48 hours, plasma membrane
sheets from these cells were attached to EM grids, fixed with 4% paraformaldehyde, 0.1%
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glutaraldehyde, and labeled with 6-nm gold directly conjugated to anti-GFP antibody and
2-nm gold conjugated to anti-RFP antibody as described previously [115, 335, 337].
Images were obtained with a transmission electron microscope at 100,000x magnification
and intact 1 μm2 areas were identified with ImageJ. Bivariate K function analysis was
performed as described [119].

Bootstrap tests were used to examine for statistical

differences between replicated point patterns and statistical significance was evaluated
against 1000 bootstrap samples.

PtdSer addback
Brain PtdSer was dissolved in chloroform (5mg/ml) in a glass vial and dried under
a vacuum. Complete growth medium was added to redissolve the lipids by sonication and
diluted to 10uM. Cells were then incubated with the lipids at 37°C for 1 hour followed by
membrane rip-off and cell fixation.

Cell counting
For shRNA knockdown studies, BxPC-3, PANC-1, MiaPaCa-2, and MOH parental
and knockdown cells were seeded at a density of 2 × 105 cells/well in six-well plates in
triplicate and counted every day for 5 days using the countess automated cell counter
(Invitrogen).

CyQuant proliferation assay
For C7 single treatment studies, HPNE (5000 cells/well), BxPC-3 (4000
cells/well), PANC-1 (4000 cells/well), MiaPaCa-2 (2000 cells/well), and MOH (1500
cells/well) were seeded in 96-well plates in triplicate. After 24 h, fresh growth medium
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supplemented with 1% DMSO or differing drug concentrations were added, and the cells
were allowed to grow for another 72 h. Cell numbers were determined by CyQuant
Proliferation Assay (Thermo Fisher Scientific) according to the manufacturer’s protocol.

XTT proliferation assay
For Simeprevir and C7 combination studies, BxPC-3 (6000 cells/well), PANC-1
(5000 cells/well), MiaPaCa-2 (2500 cells/well), and MOH (1500 cells/well) were seeded
in 96-well plates in triplicate and treated 24 hours later with drugs or control solvent
(DMSO or HCL) for 72 hours in phenol-red free media. XTT reagent/activator solution was
added to the cells as per the manufacturer’s instructions (TACS XTT Cell Proliferation
Assay, Trevigen, cat # 4891-025-K), and incubated in a 37°C 5%CO2 incubator for 30
minutes before reading the absorbance at 490 nm with a reference at 630 nm on a
Synergy2 plate reader (BioTek) to correct for any background.

Anchorage-independent growth assay
BxPC-3 (10 × 103), PANC-1 (5 × 103), MiaPaCa-2 (5 × 103), and MOH (5 × 103)
parental and knockdown cells were seeded in soft agar in six-well plates, with a base
layer of 1% agar–media mixture, and a top layer of 0.6% agar–cell suspension mix as
performed in [338]. After 2–3 wk, colonies were stained with 0.01% crystal violet and
imaged. Colony numbers were quantified by ImageJ.

Animal Experiments
All animal studies were performed under an Institutional Animal Care and Use
Committee (IACUC) approved animal protocol, in accordance with the National Institutes
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of Health Guide for the Care and Use of Laboratory Animals. Female nu/nu (#007850Outbred athymic nude) and male C57BL/6 (#000664-C57BL/6J inbred) mice were
purchased from The Jackson Laboratory (Bar Harbor, ME).

Mice xenograft tumor initiation assay
Early passage BxPC-3 or MiaPaCa-2 cells were harvested, and 2.5X106 cells
expressing an empty vector were implanted subcutaneously into the right flanks of nu/nu
mice while cells expressing shRNA of OSBPL5, OSBPL8 or both were injected into the
left flank, rendering each animal its own control. Tumor volume was measured twice a
week by an external caliper and calculated as V = (Length x Width2)/2.

IVIS imaging
0.5x106 luciferase-expressing KPC cells with or without gene knockout were
resuspended in 50μl of 1XPBS and injected directly into the pancreas after performing a
laparotomy on C57BL/6 mice. Mice were randomized into control, OSBPL8 knockout, and
OSBPL5 knockout groups, with each group containing 8 mice. Mice were imaged 1-2
times a week for 3 weeks. Prior to imaging, 150mg/Kg of D-luciferin (# MB102, Syd Labs)
was injected intraperitonially into the mice and allowed to spread for 2 minutes before
anesthetizing the mice for 3 minutes followed by image acquisition. Images were taken
by IVIS Lumina XR Imaging System (Caliper Life Sciences).

Mice xenograft drug treatments
Simeprevir and Trametinib stocks were prepared in DMSO at 100mg/ml and
22mg/ml of DMSO, respectively. Copanlisib was dissolved in PEG100 in acidified water.
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Simeprevir and Copanlisib were administered via intraperitoneal injection while
Trametinib was administered via oral gavage. Working solutions of Simeprevir and
Trametinib were administered in corn oil. Treatment was started 4 days post inoculation.
For Simeprevir single treatment, 3 and 10mgs/kgs were administered 5X/week (daily for
5 days with a 2-day break) for 6 weeks. For combination experiments the following
dosages and scheduling was followed for 6 weeks: 3mgs/kgs Simeprevir 5X/week,
0.5mgs/kgs Trametinib 3X/week, and 5mgs/kgs Copanlisib 3X/week. Tumor volume was
measured twice a week by an external caliper and calculated as V = (Length x Width2)/2.

Immunohistochemistry
Tumors were fixed in 4% paraformaldehyde and incubated overnight at 25 °C then
stored in 70% ethanol at 4 °C until paraffin embedding. Five-micron sections were cut,
deparaffinized in xylene, followed by successive dehydration in 70%, 95% and 100%,
95% ethanol. The sections were then boiled for 20 minutes in 10 mM sodium citrate for
antigen retrieval, washed in 1X PBS, and quenched with 3% H2O2 at room temperature
for 30 minutes. Tumor sections were blocked in M.O.M. blocking buffer (BMK2202; Vector
Labs) for 1 hour at room temperature and then incubated with primary antibodies 4 °C
overnight. The next day, sections were washed 5 times with 1X PBS and incubated for
45 minutes with secondary antibody for 45 at room temperature. Afterwards, sections
were washed again in 1X PBS, incubated for 30 minutes in ABC solution (PK7100; Vector
Labs), developed in diaminobenzidine (K3468; Dako) and counterstained with
hematoxylin (Thermo Fisher Scientific). Sections were then successively rehydrated in
100%, 95% and 70% ethanol. Images were taken using Eclipse 80i microscope (Nikon)
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and Digital Sight DS-VI1 camera (Nikon), and staining was quantitated using NISElements Basic Research software (Nikon).

Bioinformatic analysis using UCSC Xena browser
KRAS, OSBPL5, OSBPL8, PI4KA, EFR3A, and SACM1L mRNA expression and
KRAS mutational status in patients and their overall survival were analyzed and visualized
using data in GDC TCGA-PAAD, TCGA-LUNG, GDC-PANCAN, and TCGA TARGET
GTEx by Xena browser (https://xenabrowser.net/) [339].

Statistical analysis
Results are presented as the mean ± SEM. Prism version 5.0 (GraphPad
Software) was used for One-Way ANOVA and two-tailed t tests. Levels of significance
are labeled as: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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CHAPTER 3: THE ORP5/8 PTDSER TRANSPORT SYSTEM AS
A NOVEL TARGETABLE PATHWAY FOR KRAS INHIBITION
This chapter is based upon
Kattan, W. E., Chen, W., Ma, X., Lan, T. H., van der Hoeven, D., van der Hoeven, R., &
Hancock, J. F. (2019). Targeting plasma membrane phosphatidylserine content to
inhibit oncogenic KRAS function. Life Sci Alliance, 2(5). doi:10.26508/lsa.201900431.
Copyright permission granted on 21 May 2021.

INTRODUCTION
Preventing KRAS PM localization has been long advocated as an approach to
block oncogenic function. However early attempts to use farnesyltransferase inhibitors
(FTIs) to prevent the first step of post-translational processing that adds the KRAS
membrane anchor failed because KRAS can be alternatively prenylated by
geranylgeranyl transferase1 (GGTase1) when cells are treated with FTIs [24, 340, 341].
To identify an alternative strategy, we focused on the dependence of KRAS on PM
PtdSer. We showed previously that indirect approaches to reduce PM PtdSer by
manipulating sphingolipid and ceramide metabolism was moderately successful in
reducing KRAS oncogenesis [48, 342]. Here we evaluate direct targeting of the cellular
machinery that actively maintains PM PtdSer content. PtdSer is the major anionic lipid
on the inner leaflet of the PM comprising ~25mol% of total lipid content [343]. The
homologs Oxysterol Related Binding Proteins, ORP5 and ORP8, encoded by OSBPL5
and OSBPL8, respectively, are lipid transport proteins that function at membrane contact
sites (MCS) between the endoplasmic reticulum (ER), PM and other organelles. Both
proteins transport PtdSer from its site of synthesis in the ER to the PM, where it is
exchanged for phosphoinositide-4-phosphate (PI4P) (Figure 5) [318, 321]. Therefore, we
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hypothesized that targeting PtdSer transporters ORP5 and ORP8 would disrupt KRAS
PM localization and nanoclustering and attenuate KRAS function.

Figure 5. ORP5 and ORP8 transport PtdSer to the PM. OSBPL5 and OSBPL8 are

paralogs that encode ORP5 and ORP8. These proteins are lipid transporters involved in
lipid counter transport between the endoplasmic reticulum and the PM, specifically they
exchange phosphatidylserine (PtdSer) in the ER with phosphatidylinositol 4-phosphate
(PI4P) in the PM. The driving force of this process is a PI4P concentration gradient
whereby PI4P levels are high in the PM and are kept low at the ER by the action of the
SAC1 phosphatase which immediately hydrolyzes PI4P. OSBPL: Oxysterol Binding
Protein

Like;

obr:

Oxysterol

Binding

protein

Related;

SAC1P:

SAC1

Like

Phosphatidylinositide Phosphatase.

The human ORP family contains 12 members in 6 subfamilies categorized by
protein homology and gene organization [344, 345]. All members contain a highly
conserved lipid binding domain that can transport cholesterol or different phospholipids
[315, 346, 347]. The lipid transport domain in ORP5/8 is called the Oxysterol-bindingprotein-Related-Domain (ORD) and binds PI4P or PtdSer; binding of these lipids is
mutually exclusively because the hydrophobic pocket can only accommodate a single
lipid molecule [319]. Both ORP5 and ORP8 contain an N-terminal Pleckstrin-Homology
(PH) domain that binds to PI4P or PIP2 on the PM [317, 348-351] and a C-terminal
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hydrophobic transmembrane domain that tethers them to the ER [352-354]. Two splice
variants of ORP8 exist: ORP8S and ORP8L which has an additional 42 amino acid
acidic/negative stretch at the N-terminus. ORP5 is predominantly located at ER-PM
MCSs, while the majority of ORP8L is ER localized, and ORP8S is intermediate between
the two. The decreased levels of ORP8L at ER-PM contacts compared to ORP8S may
be due to the ORP8L-specific negative N-terminus [317]. Additionally, ORP5 contains a
cluster of basic/positive arginine residues that makes this protein especially favorable
among the three for interaction with the negatively charged inner leaflet of the PM [355].
There is some debate about how ORP5 and ORP8 mechanistically interact. Some
studies suggest that ORP5 helps recruit ORP8 to the PM when PIP2 levels rise due to
elevated PI4P content that is subsequently phosphorylated to produce PIP2. Under these
conditions ORP5 and ORP8 colocalize and directly interact with each other [317],
consistent with studies showing an increased PtdSer/PI4P exchange rate upon
dimerization [316]. By contrast, other work suggests that ORP8 binding inhibits ORP5
recruitment to the PM [355]. There is also debate on which phosphoinositide ORP8 or
ORP5 bind, with some studies accounting the difference to minor distinctions in amino
acid sequence and charge of each ORP protein [317]. More specifically, Sohn et al.
showed that ORP8, and not ORP5, may preferentially bind PIP2 because it forms only 12
H-bonds with PI4P but 16 H-bonds with PIP2 and has additional electrostatic interactions
with the two additional phosphates of PIP2 compared to PI4P. Therefore, while ORP5
activity at the PM depends on PI4P levels, ORP8 activity and recruitment depends on
both PI4P and PIP2 levels [355]. It is yet to be determined if PI4P and PIP2 carry the
same weight in terms of importance for PtdSer PM transport; however, it is clear that
PIP2 levels can regulate PtdSer exchange by recruiting more ORP8 to the ER-PM MCSs,
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or by OPR8 using PIP2 for exchange, or a combination of both mechanisms [317, 356,
357].

RESULTS
Knockdown of ORP5 and ORP8 expression inhibits PtdSer transport to the PM and
mislocalizes KRASG12V from the PM
To evaluate the effects of the ORP proteins on KRAS PM localization and
signaling, we used CRISPR/Cas9 to knock out ORP8 in CaCO-2 colorectal cancer cells
(Figure 6A). ORP8 knockout (KO) cells were then transfected with GFP-tagged
oncogenic KRAS4B (GFP-KRASG12V) or a GFP-tagged PtdSer probe (GFP-LactC2).
Intact basal PM sheets were prepared from these cells, labelled with GFP-antibodies
coupled directly to 4.5 nm gold particles and visualized by electron microscopy (EM)
[115]. We observed a significant decrease in anti-GFP immunogold labelling of both
KRASG12V (Figure 6B) and LactC2 (Figure 6C) in ORP8 KO cells, indicating
mislocalization from the inner PM. Spatial mapping analysis showed that the extent of
clustering (Lmax) of KRASG12V remaining on the PM was also significantly decreased
upon loss of ORP8 expression. Concordant with reduced KRASG12V PM binding and
nanoclustering, loss of ORP8 expression resulted in decreased MAPK signaling as
measured by ppERK output (Figure 6A). To validate the mechanistic consequences of
ORP8 knockout, we measured the PM levels of PI4P, PIP2 and PIP3. To that end, we
transfected CaCO-2 cells with GFP-tagged lipid probes and examined the extent of antiGFP immunogold labeling by EM of intact PM sheets. The GFP-FAPP1-PH probe
(FAPP1-PH) contains the pleckstrin homology (PH) domain of the FAPP1 protein, which
selectively binds PI4P [320]. The GFP-PLCδ-PH probe (PLCδ-PH) comprises the PH
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domain of PLCδ, which selectively binds PIP2 [358]. The GFP-AKT-PH probe contains
the PH domain of AKT
which binds PIP3 [359]. In
these EM experiments we
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6F) and PIP3 (Figure 6G).

Figure 6. KRAS and PtdSer, PI4P, PIP2 and PIP3 clustering and membrane
localization changes in ORP8 CRISPR knockout CaCo-2 cells. (A) CRISPR/Cas9
knockout of ORP8 in CaCO-2 cells was validated by western blotting and MAPK
signaling assayed as ppERK levels in western blots. Total ERK and β-actin levels were
used as loading controls. PM sheets prepared from CaCO-2 parental (WT) and sgORP8
cells transiently transfected with GFP-KRASG12V (B), GFP-LactC2 (C), GFP-FAPP150

PH (D), GFP-P4M-SidM (E), GFP-PLC𝛿-PH (F), or GFP-AKT-PH (G) were labeled with
anti-GFP antibodies coupled directly to 4.5nm gold particles and visualized by EM. The
amount of KRASG12V, LactC2, FAPP1-PH, P4M-SidM, PLC𝛿-PH and AKT-PH on the
PM was measured as gold particle labeling per μm2, and significant differences were
quantified using Student’s t tests. Clustering of the GFP-tagged probes were quantified
by univariate spatial analysis, summarized as Lmax values and significant differences
were assessed using bootstrap tests (± SEM, n ≥12). Representative EM images of the
calculated data is shown under each plot with their respective gold number and Lmax
values. The (x,y) coordinates of each identified gold particle on the PM sheet are plotted
to scale underneath each micrograph to more easily visualize the gold pattern. (*p<0.05,
**p<0.01, ***p<0.001, ****p<0.00001; KG12V: KRASG12V, LactC2: PtdSer probe,
FAPP1-PH and P4M-SidM: PI4P probes, PLC𝛿-PH: PIP2 probe, AKT-PH: PIP3 probe).

CaCO-2 cells do not form a well-organized confluent monolayer and are thus not
well-suited for quantitative confocal microscopy analysis. We therefore used confluent
MCF-7 breast cancer cells, to visualize and quantify KRAS and PtdSer mislocalization.
ORP5 and ORP8 were knocked down separately as well as simultaneously in MCF-7
cells (Figure 7A). Parental and knockdown cells were infected with bicistronic lentiviruses
expressing either GFP-KRASG12V or GFP-LactC2 with mCherry-CAAX, a general
endomembrane marker, and analyzed by confocal microscopy (Figure 7B). The extent
of overlap between GFP and mCherry signals, indicative of colocalization, was quantified
by Manders coefficients. The higher the Manders coefficient, the more extensive the
colocalization of KRASG12V or LactC2 with endomembranes. These experiments
showed that knockdown of ORP5 or ORP8 individually mislocalized KRASG12V and
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LactC2 from the PM to endomembranes to similar extents, with no discernable additive
effect in double knockdown cells (Figure 7C).

Figure 7. Knockdown of ORP5 or ORP8 mislocalizes KRAS and PtdSer from the
PM. (A) shRNA knockdown of ORP5 and ORP8 separately and simultaneously in MCF7 breast cancer cells was validated by western blotting and β-actin levels were used as
loading controls. (B) Parental (WT) and knockdown cells were transiently transfected
with GFP-KRASG12V and mCherryCAAX (an endomembrane marker) or GFP-LactC2
and mCherryCAAX and imaged in a confocal microscope. Representative images are
shown. (C) The extent of KRAS and LactC2 mislocalization was quantified using
Manders coefficient, which measures the extent of colocalization/overlap of GFP and
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mCherry signals. Significant differences were evaluated using Student’s t tests (± SEM,
n ≥6) (*p<0.05, **p<0.01, ***p<0.001); scale bar 20μm.

Depletion of PM PtdSer inhibits cell proliferation and anchorage-independent growth
We next evaluated the effects of ORP8 knockdown on KRAS and PtdSer
localization in a panel of pancreatic cancer cell lines that are wildtype for KRAS, such as
BxPC-3, or contain a KRAS mutation, such as PANC-1, MiaPaCa-2, and MOH. For each
cell line, multiple stable monoclonal ORP8 knockdown cells were generated using
shRNA lentiviral infection followed by puromycin selection. The use of multiple clones
was designed to examine potential clonal variation following cell line selection. As in the
model MCF-7 cell line, ORP8 knockdown caused significant mislocalization of both
KRASG12V and LactC2 from the PM in each cell line tested, with the accumulation of
both probes on endomembranes as visualized by confocal microscopy (Figure 8). We
also generated monoclonal ORP5 knockdown cells using a similar protocol, as well as
double knockdown of both ORP5 and ORP8 to assess possible compensation by one
ORP homolog in the absence of the other (Figure 9).
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Figure 8. Knockdown of ORP5 or ORP8 mislocalizes KRAS and PtdSer from the
PM in a panel of pancreatic cancer cell lines. ORP8 was knocked down by shRNA in
BxPC-3, PANC-1, MOH and MiaPaCa-2 cells. Parental (WT) and knockdown cells were
transiently transfected with GFP-KRASG12V and mCherryCAAX (an endomembrane
marker) or GFP-LactC2 and mCherryCAAX and imaged in a confocal microscope.
Representative images are shown; scale bar 20μm.
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knockdown of ORP5 and ORP8 separately and simultaneously in BxPC-3, PANC-1,
MOH and MiaPaCa-2 cells was validated by western blotting and β-actin levels were
used as loading controls.

First, we tested the effects on cell proliferation over the course of 5 days (Figure
10). In the case of the KRAS WT cell line BxPC-3, there was no discernable effect of
knockdown of either ORP5 or ORP8 alone on proliferation rate. However, the
simultaneous knockdown of both proteins modestly decreased proliferation rate. In the
case of PANC-1, which is a KRAS-independent cell line, i.e. it is not addicted to
oncogenic KRAS [361], ORP5 or ORP8 single knockdown resulted in cells growing
significantly faster than parental cells; however, double knockdown clones grew more
slowly. In contrast, single gene knockdown of either ORP homologue was sufficient to
inhibit the proliferation of KRAS-dependent MiaPaCa-2 and MOH cells. In these
proliferation assays all MOH clones tested displayed a consistent response (Figure 10),
whereas there was some variation in the behavior of different MiaPaCa2 ORP8
knockdown clones, including some that
underwent senescence in culture and
could not be analyzed further.
Figure 10. ORP5 or ORP8 knockdown
decrease

growth

rate

of

KRAS-

dependent pancreatic cancer cells.
ORP5 and ORP8 were knocked down
separately and simultaneously by shRNA
in BxPC-3, PANC-1, MiaPaCa-2 and MOH
cells. Parental and knockdown cells were
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grown in 6-well plates for 5 days and counted every day. Cell numbers of each cell line
at day 5 were normalized to their cell number at 24 hours and plotted. Significant
differences were evaluated using Student’s t tests (± SEM, n=3) (**p<0.01, ***p<0.001).
Anchorage-independent growth is a more stringent assessment of tumorigenic
potential; therefore, we analyzed colony formation in soft agar (Figure 11). MiaPaCa-2
ORP5 and ORP8 KD clones showed heterogeneous responses that correlated with their
proliferation rate; MiaPaCa-2 KD clones that grew slower also showed reduced growth
in soft agar. Double knockdown of both ORP proteins however had a more significant
effect on anchorage-independent growth than on proliferation. Knockdown of either ORP
protein completely abrogated colony formation in MOH cells.

Figure 11. ORP5 or ORP8 knockdown
decrease

anchorage-independent

growth capability of KRAS-dependent
pancreatic cancer cells.

ORP5 and

ORP8 were knocked down separately
and simultaneously by shRNA in BxPC3, PANC-1, MiaPaCa-2 and MOH cells.
Parental and knockdown cells were
seeded in soft agar, with a base layer of
1% agar-media mixture and a top layer of
a 0.6% agar-cell suspension mix in 6-well plates. After 2-3 weeks, colonies were stained
with 0.01% crystal violet and imaged. Colony numbers were quantified by ImageJ and
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significant differences were evaluated using Student’s t tests (± SEM, n=3) (*p<0.05,
**p<0.01).
Interestingly, the clonal variation in MiaPaCa-2 ORP8 KD cells also correlated
with the extent of mislocalization of LactC2 and KRASG12V as determined by confocal
microscopy (Figure 12). Conversely, knockdown of ORP8 alone had no significant effect
on the anchorage-independent growth of KRAS-independent PANC-1 cells. Of note,
PANC-1 cells were more sensitive to knockdown of ORP5 than ORP8, while ORP8
knockdown more potently affected MiaPaCa-2 and MOH cells. As in the proliferation
assays, double knockdown of both homologs had a stronger effect in all three KRASmutant

transformed

cell

lines.
Figure 12. Knockdown of
ORP8 mislocalizes KRAS
and PtdSer from the PM.
Three distinct MiaPaCa-2
ORP8

knockdown

monoclonal

lines

were

transiently transfected with
GFP-KRASG12V

and

mCherryCAAX

(an

endomembrane marker) or
GFP-LactC2

and

mCherryCAAX and imaged
in a confocal microscope.
Each

clone

exhibited
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varying degrees of KRAS and LactC2 mislocalization. Numbers denote colony number.
Representative images are shown; scale bar 20μm.
Analysis of signaling pathways revealed a paradoxical increase in MAPK signaling
in nearly all KRAS-mutant ORP5 and ORP8 KD clones, evidenced as elevated
ppERK1/2 levels (Figure 13). This likely indicates alleviation of the negative feedback on
upstream components of the RAF-MEK-ERK pathway, in turn reflecting a reduction in
the strength of KRAS signaling. One exception were the PANC-1 KD cells which showed
increased ppERK levels only when ORP5 was individually knocked down consistent with
a stronger response of these cells to ORP5 KD. Levels of pThr308AKT were increased
in MiaPaCa-2 knockdown cells compared to parental and empty vector controls,
presumably due to the accumulation of PI4P and hence PIP2 on the PM following ORP
knockdown (Figure 13), feeding into the PI3K/AKT pathway. In contrast, no pThr308AKT
was detected in either parental or knockdown MOH cells. There was no significant
difference in pThr308AKT levels between parental and knockdown cells in the PANC-1
and BxPC-3 lines. These results may possibly reflect different signaling outputs from the
different KRAS point mutations in the cell lines (MiaPaCa-2: G12C, MOH: G12R, PANC1: G12D) as well as KRAS dependency. pSer473AKT levels were elevated in KRASmutant ORP5 and ORP8 KD cells in all cell lines tested. Increased levels of YAP-1 and
EGFR activation have been previously reported to be compensatory mechanisms to
KRAS inhibition in pancreatic cancer cells [362, 363]. Across the panel of KD cells, we
saw considerable clonal variation with regard to YAP-1 and pEGFR levels (Figure 13A)
with no obvious correlation with KRAS mutational status. Finally, to evaluate whether
KRAS mutational status affects ORP5 and ORP8 basal levels, we used the isogenic
colorectal cancer cell line HCT116; the parental line harbors a heterozygous KRAS
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mutant, while its derivative line has a single WT KRAS allele after knockout of the mutant
allele via homologous recombination. ORP8 levels increased primarily in the derivative
line upon ORP5 knockdown; however, the reverse was not observed (Figure 13B.C).

Figure 13. Consequences of ORP5 and ORP8 knockdown on downstream MAPK
and PI3K/AKT signaling. (A) Protein from BxPC-3, PANC-1, MiaPaCa-2 and MOH
parental, single and double ORP knockdowns as well as cells transfected with empty
vector control (pLKO.1) were harvested and 20μg was subjected to SDS-PAGE and used
for Western blotting. EGFR, MAPK and PI3K signaling were assayed as pEGFR, ppERK
and pAKT levels, respectively. Amplification of YAP-1 was also evaluated. Total ERK,
total AKT and β-actin levels were used as loading controls. (B,C) ORP8 expression
increases upon ORP5 knockdown in KRAS WT but not KRAS heterozygous mutant cells
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in a pair of isogenic cell lines. (B) shRNA knockdown of ORP5 and ORP8 in HCT116
isogenic cell lines was validated by western blotting and β-actin levels were used as
loading controls. (C) Parental and ORP5 knockdown cells of HCT116-/WT and
HCT116Mut/WT cells were blotted for ORP8 to evaluate changes in protein expression
level upon ORP5 knockdown and β-actin levels were used as loading controls. -/WT:
cells with a single KRAS WT allele, Mut/WT: cells with one KRAS mutant allele and one
KRAS WT allele.

SUMMARY AND DISCUSSION
The role of ORP5 and ORP8 in maintaining PtdSer and PI4P levels on the PM
has been well documented [316, 318, 355, 364-366]). In this chapter however, we have
elucidated the role of this PtdSer/PI4P exchange mechanism in oncogenic KRAS
function. More specifically, we showed, for the first time, that ORP5 and ORP8 are
essential and required for proper KRAS PM localization and signaling. CRISPR/Cas9
knockout or shRNA knockdown of either protein severely depleted the PM from PtdSer,
leading to KRAS mislocalization from the PM and decreased nanocluster formation of
any remaining KRAS on the PM. This in turn led to slower growth rates of pancreatic
cancer cells and abrogated their ability of anchorage-independent growth in vitro. More
interestingly, the strongest effects were seen in cell lines reported to be dependent on
oncogenic KRAS, followed by KRAS-mutant independent cells and finally KRAS wildtype
cells that were only adversely affected when both ORP5 and ORP8 were simultaneously
knocked down. Knockdown of either ORP protein also led to decreased ppERK1/2 and
pAKT output in some cell lines, while increasing their levels in others. Both observations
can be indicative of target inhibition as an initial decrease of these downstream effectors
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alleviates their negative feedback mechanism imposed on upstream components of the
pathways.
In short, we have linked, for the first time, the ORP5/8 PtdSer/PI4P exchange
mechanism to oncogenic KRAS function and elucidated its mechanism of action. This
opens new avenues for the search of pathways and novel targets to indirectly inhibit
KRAS function. These in vitro mechanistic studies provide the groundwork for further
investigation of the effects of these targets on tumor growth in vivo and their role in
human cancers, which is the subject of the next chapter.
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CHAPTER 4: EVALUATING COMPONENTS OF THE ORP5/8
PTDSER/PI4P EXCHANGE MECHANISM AS CANDIDATE
TARGETS TO INHIBIT PANCREATIC CANCER GROWTH IN
VIVO
This chapter is based upon
1) Kattan, W. E., Chen, W., Ma, X., Lan, T. H., van der Hoeven, D., van der Hoeven, R.,
& Hancock, J. F. (2019). Targeting plasma membrane phosphatidylserine content to
inhibit oncogenic KRAS function. Life Sci Alliance, 2(5). doi:10.26508/lsa.201900431.
Copyright permission granted on 21 May 2021.
2) Adhikari, E., Kattan, W.E., Kumar, S., Zhou, P., Hancock, J.F., Counter, C.M. (2021).
Oncogenic KRAS is dependent upon an EFR3API4KA signaling axis for potent
tumorigenic activity. Nat. Commun., (conditionally accepted).

INTRODUCTION
In the previous chapter we showed that genetic knockdown of ORP5 or ORP8
mislocalized KRAS from the PM, reduced its nanoclustering, decreased proliferation and
anchorage-independent growth of pancreatic cancer cells. In this chapter, we extend our
previous in vitro findings to encompass the effects of ORP5/8 genetic knockdown on 1)
downstream signaling in a C. elegans model and 2) pancreatic cancer growth in vivo in
immune-compromised mice. We also evaluate the consequences of knocking out ORP5
and ORP8 in immune-competent mice and their eligibility to be targeted as an indirect
mechanism of KRAS inhibition. Specifically, the immune-competent syngeneic mouse
model involves CRISPR/Cas9 knockout of ORP5/8 expression in luciferase-expressing
KPC (Pdx1-Cre, LSL-KrasG12D/+, LSL-Trp53R172H/+) cells. The parental line was
established from the KPC mouse model of Pancreatic Ductal Adenocarcinoma (PDAC).
What sets this mouse model apart from others is the fact that it is a clinically relevant
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model that recapitulates what occurs in human disease, progressing from pancreatic
intraepithelial neoplasia (PanINs) to full blown PDAC [367]. In this chapter we additionally
explore the relationship of ORP5 and ORP8 with human pancreatic, lung and colorectal
cancers and how they correlate with KRAS expression and mutational status in these
cancers. We also extend our investigation to encompass other possible targets both
upstream (PI4KA and EFR3A which encode PI4KIIIa and EFR3A, respectively) and
downstream (SACM1L which encodes Sac1 phosphatase) of ORP5 and ORP8 (Figure
5). EFR3A (EFR3 Homolog A) is a component of a protein adapter complex that acts as
a regulator of PI4P synthesis by transporting PI4KIIIa from the cytosol to the PM. EFR3A
tethers itself (and the rest of the complex) to the plasma membrane by virtue of its
palmitoylated N-terminus [368, 369]. It has been established that this protein is important
for the maintenance of an active pool of PI4KIIIa on the PM [324, 370] and hence may
also be a valid drug target for KRAS inhibition by deregulating the PM-ER PI4P
concentration gradient needed for ORP5/8 function and PtdSer PM localization.

RESULTS
Knockdown of ORP5 or ORP8 inhibits oncogenic KRAS signaling in C. elegans.
We first investigated whether PtdSer ER to PM transport is relevant for KRAS
function in the model organism C. elegans, which expresses a single RAS gene, let-60,
an ortholog of KRAS4B. We performed RNAi-mediated knockdown of validated orthologs
of ORP5 and ORP8 in C. elegans carrying a mutationally activated G12D let-60 allele
(n1046), whose signaling leads to a multi-vulva (MUV) phenotype that is readily
quantifiable. Since there are no clear homologs or orthologs of ORP5 and ORP8 in the
worm, we performed blast analysis using the wormbase tool on NCBI OSBPL5 and
OSBPL8 sequences and obtained 3 hits: obr-2, obr-3 and obr-4 (Table 1). All 3
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candidates affected the MUV phenotype when tested using RNAi with obr-4
demonstrating the strongest phenotype followed by obr-2 and obr-3 (Figure 14).
Table 1. Sequence data for OSBPL5 and OSBPL8 homologs/orthologs
OSBPL5
OSBPL8
Gene

Score

E value

% Identity

Score

E value

% Identity

obr-2

104

2.00E-22

30

105

2.00E-22

30

obr-3

603

E-172

50

655

0

52

obr-4

210

5.00E-54

31

223

5.00E-58

34

Knockdown of either obr-4 or obr-2 expression potently suppressed the MUV
phenotype, with 93% and 62% of the population, respectively, displaying a single vulva.
This extent of suppression is similar to the positive controls riok-1 and hoe-1, previously
described as potent suppressors of the MUV phenotype [371, 372] (Figure 14). The
enzyme Sac1 phosphatase resides in the ER and hydrolyzes PI4P to PI, creating a PI4P
concentration gradient where it is high in the PM and low at the ER. This concentration
gradient is also the driving force of ORP5/8 function [366]. Concordantly, we see that
RNAi knockdown of sac1p (human SAC1P) also significantly inhibited the MUV
phenotype, though to a lesser degree than knockdown of ORP5/8. Importantly, viability
of organisms was not compromised upon OSBPL5, OSBPL8, or SAC1P gene silencing.
Together, these results suggest that ER to PM PtdSer transport is required to support
KRAS oncogenic signaling in vivo.
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Figure

14.

knockdown
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elegans model.
knockdown

RNAi

screen

of

OSBPL5, OSBPL8 and SAC1P orthologs in an activated let-60 C. elegans. RNAi was
induced by feeding let-60(n1046) L1 worms through adult stage with E. coli strain HT115,
producing dsRNA to target genes. The presence of the multivulva phenotype was scored
using DIC/Nomarski microscopy. Previous reports show that heo-1 and riok-1 potently
suppress the let-60 G13D multi-vulva phenotype and hence were used as positive
controls (****p<0.0001, *p<0.05).

Knockdown of either ORP5 or ORP8 inhibits the growth of KRAS-mutant tumors in a
xenograft mouse model.
To establish the effect of knockdown on tumor initiation and growth in vivo,
parental (containing an empty plasmid), single clonal ORP5, ORP8 or double
ORP5/ORP8 knockdown MiaPaCa-2 or BxPC-3 cells were subcutaneously injected into
the right and left flanks, respectively, of nu/nu immunosuppressed mice, allowing each
mouse to act as its own control. Tumors were measured twice a week and were
harvested at 6 weeks. Knockdown of either ORP protein significantly impaired tumor
growth in KRAS-mutant MiaPaCa-2 cells, while having no effect on KRAS WT cells
(Figure 15). Single knockdown had as strong an affect as double knockdown in
abrogating tumor growth, with no difference seen between ORP5 and ORP8 single knock
down.
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Figure

and/or

15.

ORP5
ORP8

knockdown inhibits
tumor

growth

of

KRAS-mutant PDAC
in vivo.

Monoclonal

shORP5, shORP8 and
shORP5/8 knockdown
MiaPaCa-2 and BxPC3 cells were injected
subcutaneously in the
left flanks of nu/nu immunosuppressed mice. Monoclonal empty vector control MiaPaCa2 and BxPC-3 cells were injected in the right flanks of the same mice to act as an internal
control. Tumors were allowed to grow for 6-8 weeks then were harvested. (One-way
ANOVA, ***p<0.005, ns: non-significant, n of each group = 8).

CRISPR/Cas9 knockout of ORP5 or ORP8 decrease anchorage-independent growth of
KPC cells and inhibits tumor growth in an immune-competent syngeneic mouse model.
To further recapitulate what occurs in human disease, we assessed the
importance of OPR5 and ORP8 in tumor initiation and maintenance in an immunecompetent syngeneic mouse model. To that end, we used a KPC (Pdx1-Cre, LSLKrasG12D/+, LSL-Trp53R172H/+) mouse pancreatic cancer cell line that we engineered
to constitutively express luciferase. Single cells were expanded to produce monoclonal
lines and the clone with the strongest luciferase signal was chosen for further
experiments. This step is important to ensure uniformity of luciferase expression to verify
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that any changes seen in signal intensity in subsequent experiments are indeed due to
changes in cell proliferation and tumor growth rates. We then used CRISPR/Cas9 to
generate monoclonal ORP5 and OPR8 knockout cells (Figure 16).

Figure 16. Validation of CRISPR-Cas9 knockout in monoclonal KPC ORP5 and
ORP8 knockout cells. DNA was extracted from monoclonal KPC ORP5 and ORP8
knockout cells, amplified via PCR and sent for Sanger sequencing. Sequencing traces
of ORP5 (A) and ORP8 (B) knockout cells were aligned to control cells transfected with
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an empty vector backbone. Arrows indicate start of designed sgRNA sequence targeting
the Cas9 enzyme to the gene, after which we see overlapping peaks, indicative of DNA
nicks and subsequent mutations. Below each trace is the translated peptide sequence.
(A) A tryptophan deletion in ORP5 was assessed as deleterious to protein function. (B)
An early stop codon in ORP8 knockout cells led to a truncated protein.

Cells containing an empty plasmid backbone were used as controls. To better
recapitulate what happens in human disease, cells were orthotopically injected into the
pancreas of immune-competent C57/BL6 mice followed by weekly IVIS (in vivo imaging
system) imaging to track disease progression. Knockout of either ORP protein drastically
inhibited tumor growth in this setting, with ORP8 knockout having a more profound effect
(Figure 17A), recapitulating what we also saw in an in vitro anchorage-independent
growth assay (Figure
17B).
Figure 17. ORP5 or
ORP8

knockout

reduces

tumor

growth rate of PDAC
in

an

immunecompetent

syngeneic
model.
Monoclonal
vector,

mouse
(A)
empty
sgORP5

knockout or sgORP8
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knockout KPC cells were injected orthotopically into the pancreases of C57/BL6 mice
and mice were imaged using the IVIS (in vivo imaging system) 2-3 a week for 3 weeks.
Student’s t test was used between each group and the control group at each time point.
(n of each group = 8, *p<0.05). (B) The same cells as in (A) were seeded in soft agar,
with a base layer of 1% agar-media mixture and a top layer of a 0.6% agar-cell
suspension mix in 6-well plates. After 2-3 weeks, colonies were stained with 0.01%
crystal violet and imaged. Colony numbers were quantified by ImageJ and significant
differences were evaluated using Student’s t tests (± SEM, n=3) (**p<0.01, ***p<0.001).

Expression levels of ORP5 and ORP8 are increased in KRAS-mutant tumors and
correlate with poor overall survival in a variety of human cancers.
High ORP5 expression has been previously shown to be associated with poorer
survival rates in patients with pancreatic adenocarcinoma [373]. To further investigate
whether this is linked to oncogenic KRAS signaling, we analyzed OSBPL5 mRNA
expression in relation to KRAS mutation status in GDC (Genomic Data Commons)
TCGA-PAAD, TCGA-LUNG and GDC TCGA-PANCAN, cohorts of pancreatic
adenocarcinoma, non-small cell lung cancer and a pan-cancer cohort comprising 33
different cancer types, respectively [339]. In all three cohorts, OSBPL5 expression was
significantly upregulated in KRAS-mutant subgroups compared to KRAS-wild-type
subgroups (Figure 18A). Additional analyses showed that increased expression of
OSBPL5 or OSBPL8 correlates with shorter overall survival times for patients in all three
cohorts (Figure 18B-C).
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Figure 18. High expression levels OSBPL5 and OSBPL8 correlate with poorer
prognosis in cancer patients. (A) Box plots indicating quartiles of ORP5 mRNA
expression level in patient samples in cohorts of pancreatic cancer (GDC TCGA PAAD,
n=223), lung cancer (TCGA LUNG, n=1299), and of 33 types of cancer (GDC PanCancer (PANCAN), n=20163) with or without KRAS mutations. Statistical significance
was analyzed with Welch’s t test. Kaplan-Meier survival plots based on top and bottom
25% expression levels of ORP5 (B) and ORP8 (C) in cohorts listed in (A). Plots were
generated using the UCSC Xena Browser.
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All components of the PtdSer/PI4P exchange mechanism are upregulated in pancreatic
cancer.
Since ORP5 and ORP8 only comprise part of the PtdSer/PI4P exchange
mechanism, we investigated whether other components were also involved in increased
tumorigenicity in KRAS-mutant cancers, specifically PDAC. We analyzed pancreatic
RNA-seq data from the TCGA TARGET GTEx study, which include expression profiles
of TCGA solid tumor samples as well and GTEx samples which are derived from normal
tissues of individuals who do not have cancer. The analysis revealed that PI4KA mRNA
levels, which encodes the PI4KIIIa enzyme essential for maintaining the PM PI4P pool,
significantly and positively correlates with KRAS expression in normal and tumor
pancreatic tissue (Figure 19A) and that PI4KA expression levels are increased in tumor
tissue (Figure 19C). As mentioned previously, PI4P is hydrolyzed in to PI after its
transport from the PM to the ER by ORP5/8, making sac1 phosphatase an equally
important factor in maintaining the PI4P concentration gradient critical for ORP5/8
function. As such, we found that mRNA levels of SACM1L, which encodes sac1
phosphatase, also significantly and positively correlates with KRAS expression (Figure
19B) and is significantly elevated in pancreatic tumors compared to normal tissue (Figure
19C).
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Figure 19. PI4KA and
SACM1L expression
levels

positively

correlate with KRAS
expression

levels

and are increased in
PDAC. Scatter plots
indicating

correlation

of mRNA expression
levels of KRAS with
(A) PI4KA (Pearson’s
rho = 0.8817) and (B)
SACM1L

(Pearson’s

rho = 0.3657) in normal and cancerous human pancreatic tissue samples (TCGA
TARGET GTEx, n=345). (C) Violin plots indicating medians of PI4KA and SAC1ML
mRNA expression levels in the same cohort as in (A and B). Statistical significance was
analyzed by Welch’s t test. Plots were generated using the UCSC Xena Browser.

The expression data we obtained pertaining to PI4KA was particularly exciting as
PI4KIIIa is a readily druggable kinase and hence may prove a more favourable candidate
for drug development efforts. However, analysis of patient sample data revealed that
PI4KA is not commonly genetically altered in KRAS-mutant cancers (Figure 20A).
Another protein called EFR3A; however, is genetically amplified in ~12% of pancreatic,
~5% of lung and colorectal cancers (Figure 20B). EFR3A is part of a protein adapter
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complex that brings PI4KIIIa to the PM to generate PI4P. Intriguingly, we found that
EFR3A amplifications co-occur with KRAS mutations to a significant degree. Genetic
alterations of PI4KA seem to significantly co-occur with EFR3A alterations but are
mutually exclusive with KRAS alterations (Figure 20C). Additionally, EFR3A expression
is upregulated in pancreatic tumors compared to non-cancerous pancreatic tissue and
positively correlates with KRAS expression (Figure 20D). These data further confirm the
importance of not just the direct components of the PtdSer/PI4P PM-ER exchange
mechanism but also its extended regulators on either side of the process (generating
and hydrolyzing PI4P), opening up a slew of potential new druggable targets to inhibit
KRAS signaling in cancer.
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Figure 20. Analysis of PI4KA and EFR3A expression levels in normal and
cancerous pancreatic tissue. Bar graphs showing the extent and nature of genetic
alterations occurring in (A) PI4KA and (B) EFR3A in pancreatic, lung and colorectal
cancer patient cohorts and (C) how their genetic states relate to one another. Plots and
statistical analyses were generated in cBioPortal (n=3176). (D) Violin plots indicating
medians of EFR3A mRNA expression level in the same samples, and a scatter plot
indicating correlation of mRNA expression levels of EFR3A with KRAS (Pearson’s rho =
0.9518) in normal and cancerous human pancreatic tissue samples (TCGA TARGET
GTEx, n=346). Statistical significance was analyzed with Welch’s t test for violin plots.
Plots were generated using the UCSC Xena Browser.

SUMMARY AND DISCUSSION
We have shown here that the importance of ORP5 and ORP8 in oncogenic KRAS
signaling seen in vitro are readily translatable in vivo. First, we showed that knocking
down orthologs of ORP5, ORP8 or Sac1 phosphatase in worms expressing the G13D
mutant of let-60 (KRAS ortholog) inhibited let-60 signaling with no adverse effects on
organism viability. This was unequivocally evident by the reversal of the multi-vulva
(MUV) phenotype, induced by mutant let-60, back to the wildtype single vulva phenotype.
Second, knockdown of ORP5 or ORP8 separately or in unison completely inhibited tumor
growth of KRAS-mutant but not KRAS wildtype cells in our xenograft mouse models.
Importantly, clonal variation and differences between single versus double knockdown
were not seen here, indicating that each ORP protein can be targeted for future drug
development efforts with a potency that emulates the inhibition of both proteins. Third,
we demonstrated that targeting ORP5 or ORP8 is also a viable option for inhibiting
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pancreatic cancer growth in an immune-competent, syngeneic orthotopic mouse model.
One setback we had experienced was that Cas9 was immunogenic and therefore
interfered with our analysis of ORP-dependent tumor growth ability. We had originally
used KPC cells stably expressing the Cas9/sgORP5, Cas9/sgORP8 or Cas9/empty
vector plasmids which elicited an immunogenic response in our female C57/BL6 mice.
This led to no tumor growth in any of the groups even by week 3. Interestingly, Medina
et al. conducted a comprehensive study involving multiple strains of mice encompassing
both male and female groups and studied their resistance to infections by group
A streptococci (GAS) bacteria including Streptococcus pyogenes -from which Cas9 is
derived-. They found that BALB/c, C57BL/10, and DBA/2 mice had the lowest bacterial
loads and longest survival times conferring highest resistance. Additionally, within these
groups, males were much more susceptible to infection than females [374]. Indeed, we
saw failure of tumor growth in female mice but not in male mice when we repeated the
experiment, indicating that growth of our KPC cells expressing Cas9 was similarly
influenced by sex, with males being much less resistant than females. The authors
suggested that the reason may be because the resistance loci is located on the X
chromosome or on an autosomal chromosome that is sex-restricted in expression [374].
These observations indicate the importance of taking into consideration multiple factors
regarding the use of mouse models and the context in which they are used.
Finally, we showed that high expression levels of OSBPL5 or OSBPL8 in multiple
cancer types is associated with poor overall survival in patients. Additionally, all
components of the PtdSer/PI4P exchange mechanism are transcriptionally upregulated
in pancreatic cancer and positively correlate with KRAS expression. This ties back nicely
with our C. elegans observation that showed knockdown of different components of this
mechanism all inhibited mutant let-60 signaling and the MUV phenotype.
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The consistent findings demonstrating the importance of the PtdSer/PI4P
exchange mechanism for cancer in cell lines, worms, mice and humans signifies the
validity of targeting the components of this mechanism for cancer therapy. The
essentiality of this mechanism for KRAS signaling is emphasized as it is conserved from
worms to humans and introduces multiple new drug candidates for the development of
treatments for KRAS-driven cancers. It also provides valuable insights on how
phospholipids can regulate oncogene signaling and how they and their respective
regulators can also be targeted to exploit tumor vulnerabilities.
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CHAPTER 5: REPURPOSING PI4KA INHIBITORS FOR THE
TREATMENT OF KRAS-MUTANT PDAC
This chapter is based upon
1) Kattan, W. E., Chen, W., Ma, X., Lan, T. H., van der Hoeven, D., van der Hoeven,
R., & Hancock, J. F. (2019). Targeting plasma membrane phosphatidylserine
content

to

inhibit

oncogenic

KRAS

function.

Life

Sci

Alliance,

2(5).

doi:10.26508/lsa.201900431. Copyright permission granted on 21 May 2021.
2) Adhikari, E., Kattan, W.E., Kumar, S., Zhou, P., Hancock, J.F., Counter, C.M.
(2021). Oncogenic KRAS is dependent upon an EFR3API4KA signaling axis for
potent tumorigenic activity. Nat. Commun., (conditionally accepted).
3) Kattan, W. E., & Hancock, J. F. (2020). RAS Function in cancer cells: translating
membrane biology and biochemistry into new therapeutics. Biochemical
Journal, 477(15), 2893-2919. https://doi.org/10.1042/BCJ20190839. This article
was published open access under a Creative Commons CC and does not require
permission for re-use by authors.

INTRODUCTION
In the previous chapter, we showed that targeting the PM PtdSer/PI4P exchange
mechanism is a valid approach for inhibiting KRAS-mutant cancer in vitro and in vivo and
that this correlated well with human patient data regarding overall survival and gene
expression levels of the different components involved in ensuring proper PtdSer levels
on the PM. The most exciting observation we made was that PI4KIIIa enzyme activity
may be extremely important for downstream KRAS function, which was evident not just
from analyzing PI4KA data, but also EFR3A data, providing consistency to our thought
process. Therefore, in this chapter, we further interrogate the role of EFR3A on KRAS
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PM localization and nanoclustering as well as on PtdSer levels on the PM. EFR3A is
implicated in some diseases such as autism [375] but as of yet, has not been linked to
any cancers. To make use of the fact that PI4KIIIa is a very readily druggable target, we
also investigate the repurposing of selective small molecule tool compounds and
commercially available PI4KIIIa inhibitors for the treatment of KRAS-mutant PDAC. This
is an important aim since no inhibitors of ORP5 or ORP8 have been described but
PtdSer/PI4P exchange can be inhibited by targeting PI4KIIIα upstream of this pathway.
As stated previously, PI4KIIIα converts phosphatidylinositol (PI) to phosphatidylinositol4-phosphate (PI4P) at the PM, which is then exchanged for PtdSer from the ER via ORP5
and ORP8 [322, 324]. The driving force of this process is a PI4P concentration gradient
which is kept high at the PM and low at the ER by Sac1 phosphatase which hydrolyzes
PI4P back to PI. Treatment with the selective class III PI4Kα inhibitor compound 7 (C7)
[264, 323, 376] or other PI4KIIIa inhibitors such as Simeprevir should dissipate the PI4P
concentration gradient between the PM and ER, functionally inhibiting ORP5 and ORP8.
Since PI4KIIIα provides the driving force for both ORP5 and ORP8, inhibition should
phenocopy a knockdown of both homologs.

RESULTS
EFR3A or EFR3B knockout mislocalizes PtdSer and KRAS from PM and disrupts
KRAS nanoclustering
Two isoforms of EFR3 exist: EFR3A and EFR3B and so we evaluated their roles
on PtdSer PM levels and KRAS PM localization and nanoclustering. First, to examine
whether EFR3 knockout had the desired effect of depleting PM PI4P levels, HEK-HT
cells with single or double CRISPR/Cas9 knockout of EFR3A (sgEFR3A) and EFR3B
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(sgEFR3B), along with empty vector control cells, were transiently transfected with GFPP4M-SidM, a PI4P probe that specifically recognizes the plasma membrane pool of PI4P
[360].

Intact basal plasma membrane sheets were prepared from these cells and

labelled with anti-GFP antibodies directly coupled to gold nanoparticles and imaged
using electron microscopy (EM) as described in Chapter 3. As can be seen in (Figure
21A), the amount of PI4P on the PM, represented by gold particle number in those cells,
was reduced to less than half in knockout cells compared to controls. Decreased PM
PI4P should lead to the dissipation of its PM-ER concentration gradient, functionally
inhibiting ORP5/8 function and effectively inhibiting PtdSer transport to the PM. To that
end, the same HEK-HT cells were transiently transfected with the PtdSer biosensor GFPLactC2 and their plasma membrane sheets analyzed by immuno-EM. As expected,
knockout cells had a significant decrease in GFP-LactC2, with EFR3A knockout having
a stronger effect (Figure 21B,C). Next, we evaluated the effects EFR3A/B knockout on
KRAS by transiently transfecting the same HEK-HT cells with GFP-KRASG12V and
analyzing plasma membrane sheets by EM. Consistent with our previous data showing
that decreased PM PtdSer leads to decreased PM KRAS localization and
nanoclustering, knockout of either EFRA3 isoform was sufficient to significantly decrease
the amount of KRASG12V gold labeling (Figures. 21D,F), indicative of KRAS
mislocalization from the inner PM. Spatial mapping of nanogold point patterns of 20-30
images per sample were analyzed by the univariate K-Function expressed as L(r)-r.
Values of L(r)-r greater than 1 (= 99% CI for a random pattern) indicate significant
clustering, and the peak value of the function termed Lmax serves as a useful summary
statistic that quantifies the extent of clustering [119]. Loss of one or more EFR3 isoforms
was found to reduce Lmax, and hence KRASG21V nanoclustering (Figure 21E), with a
slightly stronger effect in sgEFR3A and sgEFR3A/B cells, mirroring the results seen with
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LactC2. As a control, we looked at localization and nanoclustering of HRASG12V as
PtdSer content does not affect HRAS PM localization or nanoclustering. As can be seen
in (Figure 21G and H), PM localization of HRASG12V was unaffected by EFR3A or
EFR3B knockdown, further demonstrating that the effects we observed are KRAS
specific and mediated through PtdSer PM levels. Finally, we performed a rescue
experiment to validate our findings that what we have seen is indeed due to PtdSer
depletion. Addition of exogenous PtdSer for 60 minutes prior to plasma membrane sheet
preparation rescued PM localization (Figure 22I) and nanoclustering (Figure 21J) of
KRASG12V in sgEFR3A/B HEK-HT cells transiently expressing GFP-KRASG12V.
Importantly, we confirm that this increase in KRASG12V PM localization and
nanoclustering was indeed a result of increased PM PtdSer levels, as addition of PtdSer
to sgEFR3A/B HEK-HT cells transiently expressing GFP-LactC2 increased the amount
of immuno-gold labelled GFP-LactC2 (Figure 22K). Thus, EFR3A loss reduces PM PI4P,
PtdSer, and KRAS and reduces the extent of nanoclustering of any remaining KRAS on
the plasma membrane.
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Figure 21. Knockout of EFR3A or EFR3B mislocalizes PtdSer and KRAS from PM
and disrupts KRAS nanoclustering. PM sheets from human HEK-HT cells stably
infected with a lentivirus(es) encoding Cas9 with no sgRNA (vector) or the indicated
sgRNAs and transiently transfected with (A) GFP-P4M-SidM, (B,C) GFP-LactC2, (D-F)
GFP-KRASG12V or (G,H) GFP-HRASG12V were labeled with anti-GFP antibodies
coupled directly to 4.5nm gold particles and visualized by EM. The amount of GFP-P4MSidM, GFP-LactC2, GFP-KRASG12V, GFP-HRASG12V was measured as gold particle
labeling per μm2, and significant differences were quantified using Student’s t tests.
Clustering of (E) GFP-KRASG12V and (H) GFP-HRASG12V were quantified by
univariate spatial analysis, summarized as Lmax values and significant differences were
assessed using bootstrap tests. (I-K) sgEFR3A/sgEFR3B HEK-HT cells transiently
transfected with GFP-KRASG12V or GFP-LactC2 were incubated with 10uM brain
PtdSer for 1 hour prior to fixation and labelling with gold conjugated anti-GFP antibodies,
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and the (I) amount and (J) clustering of GFP-KRASG12V and (K) amount of LactC2 were
quantified as described above (±SEM, n ≥ 20). Representative EM images of the
calculated data is shown in (C and F). The (x,y) coordinates of each identified gold
particle on the PM sheet are plotted to scale underneath each micrograph to more easily
visualize the gold pattern. (*p < 0.05, **p < 0.01, ***p < 0.001; LactC2: PtdSer probe,
P4M-SidM: PI4P probe).

Components of the PI4KIIIa transport complex co-cluster with KRAS.
As mentioned above, EFR3A/B is part of an adaptor protein complex to transport
PI4KIIIa from the cytosol to the PM. This complex also includes FAM126A and TTC7A
or TTC7B, which serve as scaffolding proteins stabilizing PI4KA at the plasma membrane
[368, 377, 378]. EFR3A was previously reported as a hit in a BirA-mediated proximity
labeling experiment to identify the RAS interactome [379]; hence we looked into whether
EFR3A and the rest of the components of the adaptor complex co-localize with KRAS.
293T cells were transiently co-transfected with GFP-KRASG12V and mCherry-EFR3A,
mCherry-EFR3B, mCherry-TTC7A, or mCherry-FAM126A. 293T cells co-transfected
with GFP-KRASG12V and RFP-KRASG12V, or GFP-KRASG12V and RFP-tH (the
minimal C-terminal anchor of HRAS) served as positive and negative controls for proteins
that extensively co-cluster or spatially segregate, respectively. Intact basal plasma
membrane sheets prepared from these cells and attached to copper EM grids were fixed
and co-labeled with GFP-specific and RFP-specific antibodies directly conjugated to 6nm
and 2nm gold nanoparticles, respectively. The plasma membrane sheets were imaged
by EM and co-localization between the 6nm and the 2nm gold particle distributions was
quantified using bivariate K-functions expressed as Lbiv(r)-r. As a summary parameter
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to quantify the extent of co-clustering, we use a defined integral of the Lbiv(r)-r function
termed Lbiv-Integrated (LBI). LBI values <100 (the 95% C.I.) indicate no significant coclustering, whereas the higher the LBI value the more extensive the co-localization of the
2nm and 6nm gold distributions [117, 119]. This analysis revealed that EFR3A, EFR3B,
TTC7A, and FAM126A all co-cluster with KRASG12V to an extent that is similar to GFPKRASG12V co-clustering with RFP-KRASG12V with LBI values significantly higher than
that of our GFP-KRASG12V/RFP-tH negative control (Figure 22). Conversely, the low
LBI value for RFP-KRASG12V and GFP-tH illustrates that proteins ectopically expressed
on the plasma membrane do not always co-localize on the nanoscale. Collectively these
data support the recruitment of EFR3A to activated KRAS, increasing the retention and
nanoclustering of KRAS at the plasma membrane.
Figure 22. All components
of

the

complex

EFR3A

adaptor

co-cluster

with

KRAS on the inner plasma
membrane.
index

(LBI)

Co-clustering
measured

as

mean ± SEM of the gold
particles per 1μm2 of plasma membrane sheets calculated from gold-conjugated, antiGFP
antibody and anti-RFP antibody in EM micrographs of plasma membrane sheets from
human 293T cells co-expressing GFP-KRASG12V and TTC7A-mCherry, FAM126AmCherry, EFR3A-mCherry, or EFR3B-mCherry. TEM analysis was based on 15-20
images and bootstrap tests were used to examine for statistical differences between
replicated point patterns and statistical significance was evaluated against 1,000
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bootstrap samples. *p < 0.02 and **p < 0.001 compared to the tH negative control where
it is known that tH does not co-cluster with KRAS.

PI4KIIIa inhibition mislocalizes PtdSer and KRAS from the plasma membrane
Madin-Darby canine kidney (MDCK) cells stably expressing GFP-KRASG12V and
mCherry-CAAX (a general endomembrane marker), or GFP-LactC2 and mCherry-CAAX
were treated with C7 for 48 hours and analyzed by confocal microscopy. Treatment with
the inhibitor potently mislocalized both LactC2 and KRASG12V in a dose-dependent
manner, with significant mislocalization seen at 30µM (Figure 23A, B), consistent with
the previously reported concentrations of C7 required to reduce cellular PIP2 and PIP3
levels (IC50= 30µM) [376]. To further quantify the amount of KRASG12V and LactC2 on
the PM as well as the extent of nanoclustering following drug treatment, intact basal PM
sheets of MDCK cells were labeled with gold-conjugated anti-GFP antibodies 48 hours
after treatment with 30µM of C7 and analyzed by EM. C7 treatment caused significant
mislocalization of both KRASG12V and LactC2 from the PM and decreased their
nanoclustering (Figure 23C).
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Figure 23. PI4KIIIα inhibition mislocalizes KRAS and PtdSer from PM. (A) MDCK
cells stability expressing GFP-KG12V and mCherryCAAX or GFP-LactC2 and
mCherryCAAX were treated with DMSO or the PI4KIIIα inhibitor C7 for 72 hours at
varying concentrations then imaged with confocal microscopy. Representative images
shown. (B) The extent of KRAS and LactC2 mislocalization was quantified using
Manders coefficient, which measures the extent of colocalization/overlap of GFP and
mCherry signals. Significant differences were quantified using Student’s t tests (± SEM,
n ≥5) (C) Basal plasma membrane sheets from MDCK cells in (A) treated with 30μM of
C7 for 48 hours were prepared and labeled with anti-GFP antibodies coupled directly to
4.5nm gold particles and visualized by EM. The amount of KRASG12V and LactC2 on
the PM was measured as gold particle labeling per μm2, and significant differences were
quantified using Student’s t tests. KRAS and LactC2 clustering were quantified by
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univariate spatial analysis, summarized as Lmax values and significant differences were
assessed using bootstrap tests (± SEM, n ≥12). (*p<0.05, **p<0.01, ***p<0.001; KG12V:
KRASG12V, LactC2: PtdSer probe), scale bar 20μm.

We have identified another PI4KIIIα inhibitor, Simeprevir [380], which also
selectively and potently mislocalized KRAS from the plasma membrane (Figure 24A).
MDCK cells stably expressing GFP-KRASG12V or GFP-LactC2 along with mCherryCAAX, were treated with 200nM of Simeprevir for 72 hours and analyzed by confocal
microscopy. Manders coefficient was used to quantify the extent of overlap between GFP
and mCherry signals to evaluate the extent of colocalization between KRASG12V or
LactC2 and endomembranes; with higher values correlating to increasingly higher
internalization from the PM into the cytoplasm. Both LactC2 and KG12V were
significantly mislocalized from the PM in the treatment group compared to DMSO-treated
controls (Figure 24B).
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Figure 24. Simeprevir, mislocalizes KRAS and PtdSer from PM in the nanomolar
range. (A) MDCK cells stability expressing GFP-KG12V and mCherry-CAAX or GFPLactC2 and mCherry-CAAX were treated with DMSO or the PI4KIIIα inhibitor Simeprevir
for 72 hours at varying concentrations then imaged with confocal microscopy.
Representative images shown. (B) The extent of KRAS and LactC2 mislocalization was
quantified

using

Manders

coefficient,

which

measures

the

extent

of

colocalization/overlap of GFP and mCherry signals. Significant differences were
quantified using Student’s t tests (± SEM, n ≥5) (*p<0.05, **p<0.01, ***p<0.001; KG12V:
KRASG12V, LactC2: PtdSer probe), scale bar 20μm.
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PI4KIIIa inhibition reduced cancer cell proliferation, clonogenic potential and
anchorage-independent growth in vitro and KRAS signaling in vivo
To recapitulate ORP5/8 knockdown effects, we treated a panel of pancreatic
cancer cells with PI4KIIIa inhibitors to determine selective inhibition of KRAS-mutant
lines. We tested the effects of C7 on cell proliferation in a panel of pancreatic cancer cell
lines as well as the immortalized pancreatic cell line HPNE. 11 different concentrations
of C7 were tested ranging from 1nM to 30μM. The results show that C7 had no effect on
the non-transformed HPNE cell line. All transformed cells were sensitive to C7 but the
calculated IC50 values for growth inhibition were much lower for KRAS mutant than KRAS
WT cells, with the most sensitive lines being the KRAS-dependent MOH and MiaPaCa2 lines (Figure 25A).
Since C7 selectively inhibited the growth of KRAS-mutant pancreatic cancer cells,
we therefore sought to evaluate its efficacy in combination with inhibitors of MEK
(Trametinib), ERK (LY3214996) and PI3K (Copanlisib). We treated a panel of human
pancreatic cancer cells encompassing WT (BxPC-3) and mutant KRAS (MiaPaCa-2,
MoH and PANC-1) cell lines in triplicate with DMSO as a control, C7 alone, each of the
inhibitors alone and in combination with C7 at 0.5x and 0.25x of the calculated IC50
doses of each inhibitor (Table 2). The number of viable cells were measured 72 hours
later and normalized to DMSO control treated cells and are depicted in (Figure 25B) as
the percent of viable cells. The degree of synergy was determined by calculating the
combination index (CI) using the Chou-Talalay method. Briefly, the CI is more than 1 if
there is an additive effect, is less than 1 if there is a synergistic effect, and equals 1 if
there is an antagonistic effect [381]. As can be seen in (Figure 25C), combining C7
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treatment with each of the inhibitors had additive or synergistic responses in all cell lines
except the KRAS-WT BxPC-3 line.
Table 2. IC50 values for several growth inhibitors in proliferation and clonogenic assays

IC50 value (uM)
Proliferation Assay
Drug/Cell line
BxPC-3
C7
27
LY3214996
4.4
Trametinib
0.0037
Copanlisib
0.94
Clonogenic Assay
Simeprevir
LY3214996
Trametinib
Copanlisib

N/A
N/A
N/A
N/A

PANC-1
2.3
10
2.5
0.0486

MiaPaCa-2
10
4
0.0094
0.104

MoH
13.8
3.2
0.005
0.051

6
5
5
0.024

6
2
0.005
0.052

6
1.6
0.0026
0.0256

Simeprevir treatment alone did not significantly decrease proliferation of a panel
of KRAS-mutant pancreatic cancer cells (data not shown) and so we evaluated its effects
on the colony formation ability of these cells. Cells were seeded at low densities in
triplicate and treated 24 hours later with varying doses of Simeprevir. Fresh media/drug
mixture (identical to the C7 experiment above) was added every 72 hours for the duration
of 2 weeks. Cells were then fixed and stained with crystal violet and colonies were
counted using ImageJ. In contrast to the proliferation assay, we see that Simeprevir
reduced the colony formation potential of these cells in a dose-dependent manner
(Figure 26A) with more potent results seen when combined with the MEK inhibitor
Trametinib, the ERK inhibitor LY3214996 or the PI3K inhibitor Copanlisib (Figure 26B,C).
Similarly, these cells were seeded for a soft-agar assay, with increasing concentrations
of media/Simeprevir mixture added as a feeder layer every 72 hours for the duration of
2-3 weeks. This is a more stringent assay than typical clonogenic assays and more
closely depict in vivo conditions of anchorage-independent growth. Cells were fixed and
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stained with crystal violet, and colonies were counted using ImageJ. Consistent with the
clongenic assay, Simeprevir treatment reduced anchorage-independent growth of these
cell lines in a dose-dependent manner (Figure 26D).
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then counted (mean ± SEM, n =3) (B) BxPC-3, MiaPaCa-2, PANC-1 and MOH cells were
seeded as in (A). After 24 hours, media was replaced with fresh growth medium
supplemented with 1% DMSO, ¼ or ½ of the calculated IC50 of each indicated drug as
a single or combination treatment. Cells were counted 72 hours later (mean ± SEM, n
=3) (*p<0.05, **p<0.01). (C) The combination index (CI) of each combination treatment
was calculated using the Chou-Talalay method (CI = 1: additive effect, CI < 1: synergistic
effect, CI > 1: antagonistic effect).

Figure 26. Simeprevir treatment decreases anchorage-independent growth and
clonogenic capability of KRAS-mutant pancreatic cancer cells. (A) PANC-1,
MiaPaCa-2 and MOH cells were seeded at low densities in a 6-well plate. After 24 hours,
fresh growth medium supplemented with 1% DMSO or increasing Simeprevir
concentrations were added and cells were allowed to grow for another 2 weeks and then
fixed with 0.01% crystal violet. (B) The same cells were seeded as in (A). After 48 hours,
fresh growth medium supplemented with 1% DMSO, ¼ or ½ of the calculated IC50 of
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each indicated drug as single or combination treatment was added. Cells were allowed
to grow for another 2 weeks and then fixed with 0.01% crystal violet and counted using
ImageJ using the colony counter plugin [382] to measure the %area of each well covered
by colonies. Colonies were also counted in ImageJ. Data was plotted as
(area%)*(number of colonies) to obtain “colony parameter” and plotted (mean ± SEM, n
=3). Significant differences were evaluated using Student’s t test (*p<0.05, **p<0.01). (C)
The combination index (CI) for colony parameter values of each combination treatment
in (B) was calculated using the Chou-Talalay method (CI = 1: additive effect, CI < 1:
synergistic effect, CI > 1: antagonistic effect). (D) The same cells were seeded in soft
agar, with a base layer of 1% agar-media mixture and a top layer of a 0.6% agar-cell
suspension mix in 6-well plates. Increasing concentrations of Simeprevir were added in
the feeder layer every 72 hours. After 2-3 weeks, colonies were stained with 0.01%
crystal violet and imaged. Colony numbers were quantified by ImageJ.

We also evaluated the efficacy of Simeprevir and C7 on KRAS signaling inhibition
in vivo by utilizing a C. elegans model expressing a mutationally activated G13D let-60
allele (n1046). Let-60 is the ortholog of KRAS4B, and the only RAS gene in this
organism. In its mutant form, let-60 signaling results in the formation of multiple vulva
(MUV phenotype) which are readily quantifiable, providing a straightforward readout of
signaling activity. Our data shows that C7 and Simeprevir can block the expression of
the MUV phenotype in let-60(n1046) worms in a dose-dependent manner (Figure 27).
We observed that C7 is more potent compared to Simeprevir in suppressing the MUV
phenotype. In these experiments, we did not observe any changes in the development
of the worms in the presence of C7 or Simeprevir compared to the DMSO treated worms.
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This suggests C7 and Simeprevir do not show any toxicity effects under our experimental
conditions.
Figure

27.

PI4KIIIa
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KRAS signaling in activated let60 C. elegans model.
each

indicated
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working
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solution or vehicle control was
added to the wells in a 12-well
tissue culture plate. Approximately
100 L1 larvae (C. elegans strain
MT2124) contained in 20ml was
added to each well using a sterile
micropipette.

The

plates

were

incubated at 20ºC. The drug concentrations and vehicle control were tested in duplicates.
The presence of the multivulva phenotype was scored using DIC/Nomarski microscopy
(n=125 worms per treatment) (*p<0.05, ****p<0.0001).

Simeprevir inhibits tumor growth in mouse models of PDAC and has synergistic effects
with MEK and PI3K inhibitors
Consistent with our in vitro and C. elegans data, we observed a dose-dependent
response to Simeprevir treatment in mouse xenograft models. Nu/nu immunosuppressed
mice were subcutaneously injected with MiaPaCa-2 cells and then treated 5x a week
with DMSO, 3 or 10 mg/Kg of Simeprevir for 6 weeks. We observed a dose-dependent
response in inhibiting tumor growth (Figure 28A); however, 10mg/Kgs 5x a week proved
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to be too toxic at this dose. Immunohistochemistry staining of sectioned tumor samples
with Ki67 showed no significant decrease in proliferation in the treatment group, but
showed significantly increased cleaved caspase-3, indicative of increased apoptosis in
the treatment group (Figure 28B).
We next evaluated the effects of combination treatments of Simeprevir with
Trametinib (MEK inhibitor), Ulixertinib (ERK inhibitor), or Copanlisib (PI3K inhibitor) to
test for synergistic or additive effects. As can be seen in (Figures 28C and D) Combining
Simeprevir with Trametinib or Copanlisib more potently attenuated tumor growth
compared to either agent alone, with no significant difference seen when combined with
Ulixcertanib (data not shown).
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Figure 28. Simeprevir attenuates tumor growth of KRAS-mutant PDAC in vivo and
is more effective when combined with MEK and PI3K inhibitors. MiaPaCa-2 cells
were injected subcutaneously in the right flanks of nu/nu immunosuppressed mice. (A)
Mice were treated with either 3 or 10 mg/Kg of Simeprevir for 6 weeks and tumors were
harvested. (B) Quantification of IHC staining for cleaved caspase-3 and Ki67 in tumors
harvested from (A). (C,D) Treatment started 4 days after injection with either DMSO,
single or combination treatment of Simeprevir, Trametinib (MEK inhibitor) or Copanlisib
(PI3K inhibitor). Tumors were allowed to grow for 6-8 weeks and were harvested.
Student’s t test was used to determine significance between tumor sizes of different
treatment groups at each time point (*p<0.05, n of each group = 8).

SUMMARY AND DISCUSSION
Kinases are the most readily druggable type of proteins and hence, in this chapter
we focused on PI4KIIIa to evaluate its potential at as a drug candidate in pancreatic
cancer. We showed the importance of PI4KIIIa indirectly by knocking out its transporter
to the PM, EFR3A. Loss of EFR3A significantly mislocalized PtdSer from the PM and
decreased the amount and extent of clustering of KRAS on the PM. This was expected
as EFR3A loss led to decreased PM PI4P levels, dissipating the PI4P concentration
gradient essential for ORP5/ORP8 function. This explanation was validated by two
observations: 1) HRAS, which does not depend on PtdSer for its PM localization and
nanoclustering, was unaffected by EFR3A knockout, and 2) supplementation of
exogenous PtdSer restored KRAS PM localization and nanoclustering. Like other
components of the PtdSer/PI4P exchange mechanism discussed in the previous
chapter, EFR3A is significantly overexpressed in pancreatic tumor tissue compared to
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healthy pancreatic tissue and its expression positively correlates with that of KRAS.
Additionally, EFR3A is part of a complex of adaptor proteins all of which transport
PI4KIIIa to the PM and have all been shown here to colocalize with KRAS on the PM.
We have shown the potential of pharmacologically inhibiting the PtdSer/PI4P
exchange mechanism for the treatment of pancreatic cancer. Two PI4KIIIa inhibitors
were evaluated, C7 and Simeprevir, both of which significantly mislocalized PtdSer and
KRAS from the PM and reduced KRAS nanoclustering. C7 selectively inhibited the
growth of pancreatic cancer cells over normal immortalized cells with the most potent
effects seen on KRAS-dependent cancer cells. C7 also synergized with classical MAPK
and PI3K inhibitors in MiaPaCa-2 and PANC-1 cells, and had an additive effect in MoH
cells. Simeprevir has proven a more alluring drug candidate as it showed efficacy in
misloclaizing PM KRAS in the nanomolar range in vitro and is FDA-approved for the
treatment of Hepatitis C in humans. Simeprevir was able to reduce clonogenic potential
and anchorage-independent growth in a panel of pancreatic cancer cells in vitro and
modestly reduce tumor growth in vivo with stronger results seen when combined with
Trametinib or Copanlisib.
Simeprevir is safely used in Hepatitis C patients and more potently affects virally
infected cells because the Hepatitis C virus highly upregulates PI4KIIIa activity in these
cells [383]. Following this rationale, we hypothesize that Simeprevir will more potently
affect cancer cells as they significantly upregulate PI4KA gene expression. Taken
together, these results champion the notion of targeting PI4KIIIa in KRAS-mutant
cancers and repurposing Simeprevir for this purpose.
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CHAPTER 6: DISCUSSION
This chapter is based upon
1) Kattan, W. E., Chen, W., Ma, X., Lan, T. H., van der Hoeven, D., van der Hoeven,
R., & Hancock, J. F. (2019). Targeting plasma membrane phosphatidylserine
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doi:10.26508/lsa.201900431. Copyright permission granted on 21 May 2021.
2) Adhikari, E., Kattan, W.E., Kumar, S., Zhou, P., Hancock, J.F., Counter, C.M.
(2021). Oncogenic KRAS is dependent upon an EFR3API4KA signaling axis for
potent tumorigenic activity. Nat. Commun., (conditionally accepted).
3) Kattan, W. E., & Hancock, J. F. (2020). RAS Function in cancer cells: translating
membrane biology and biochemistry into new therapeutics. Biochemical
Journal, 477(15), 2893-2919. https://doi.org/10.1042/BCJ20190839. This article
was published open access under a Creative Commons CC and does not require
permission for re-use by authors.

We have shown here that maintenance of PM PtdSer levels is absolutely required
to maintain KRAS PM localization and hence oncogenic function and thus knockdown of
any component of the ORP5/8 ER to PM PtdSer transport process abrogates KRAS
function. First, shRNA knockdown or CRISPR/Cas9 knockout of ORP5 or ORP8
mislocalized PtdSer and KRAS from the PM and decreased the extent of KRAS PM
clustering in human pancreatic, breast and colorectal cancer cells. Second, loss of ORP5
or ORP8 concordantly inhibited the proliferation and anchorage-independent growth of
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KRAS-dependent pancreatic cells in vitro and tumor growth in vivo. Third, inhibiting
PI4KIIIα reduced PtdSer and KRAS PM levels sufficiently to selectively abrogate the
growth of KRAS-dependent pancreatic cancer cells and had synergistic or additive
effects when combined with other PDAC inhibitors in vitro and in vivo. Finally, these
observations have clinical correlates in that PDAC patients with higher expression levels
of OSBPL5 or OSBPL8 have poorer clinical outcomes, and more generally, KRAS
mutant status is associated with higher OSBPL5 expression across multiple cancer
types, and higher PI4KA, EFR3A and SAC1ML expression in PDAC. These clinical
correlates are consistent with selection for more robust maintenance of PM PtdSer levels
to support KRAS oncogenesis.

Linking ORP5 and ORP8 to KRAS-dependent signaling and tumorigenicity
Recent work suggests that ORP5 is primarily responsible for PtdSer and PI4P
trafficking at ER-PM membrane contact sites, and that ORP8 may only be recruited to
these sites upon PIP2 accumulation. Under conditions of PIP2 accumulation, ORP8 can
also exchange PIP2 for PtdSer [355]. Therefore, knocking down ORP5 would lead to an
accumulation of PI4P at the PM and hence an increase in PIP2 levels, which would lead
to ORP8 recruitment to the PM and at least partial restoration of PtdSer PM levels by the
dual action of ORP8 as a PtdSer/PI4P and PtdSer/PIP2 exchanger [316]. This would
explain why we did not see an increase of ORP5 in ORP8 HCT116 knockdown cells, but
saw an increase of ORP8 when ORP5 was knocked down [355]. Whether PIP2 is more
important than PI4P for PtdSer transport to the PM and cannot be compensated for,
remains to be determined. However, the importance of each homolog seems to be cell
line specific, as we noticed that PANC-1 cells were more sensitive to ORP5 knockdown,
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while MiaPaCa-2 cells were more sensitive to ORP8 knockdown. ORP5/8 have been
reported to also function at ER-mitochondria membrane contact sites and knockdown of
either ORP leads to altered mitochondrial morphology and reduced oxygen consumption
[365]. However, it appears that ORP5 interacts more extensively with mitochondrial outer
membrane proteins, so it might play a more important role than ORP8 here. It has also
been reported that KRAS-independent lines (RSK-dependent) depend on oxidative
phosphorylation and have increased reactive oxygen species (ROS) while KRASdependent lines rely on glycolysis [365, 384]. Together, this may be a possible
explanation for the increased sensitivity of PANC-1 cells to ORP5 knockdown.
Nonetheless, all cell lines were more sensitive to the simultaneous knockdown of both
ORP5 and ORP8 compared to either one alone. One potential method to partially sustain
PtdSer levels on the PM in double knockdown cells may be through increased vesicular
transport of PtdSer through recycling endosomes, which are enriched with this
phospholipid [314]. In a recent paper, Venditti et al. (2019) showed that ORP10 transfers
PtdSer from its site of synthesis at the ER to the trans-Golgi (TGN) and that TGN PtdSer
levels correspond to activity levels of phosphatidylserine synthase I in the ER [385]. They
also showed that ORP10 knockdown resulted in significant reduction of Golgi PtdSer
levels but no change in PM PtdSer levels. To this end, we would speculate that the Golgi
pool of PtdSer does not contribute, at least in a noticeable way, to the PM levels of
PtdSer, and hence of KRAS. However, we still do see PtdSer and KRAS located on the
PM of ORP5/ORP8 double knockdown MCF-7 cells and in MDCK cells treated with
PI4KIIIa inhibitors. Thus, PtdSer that accumulates in the ER due to ORP5/8 inactivation,
may be shuttled to the TGN via ORP10 and transported to the PM via vesicular transport.
However, since the PM levels of KRAS and PtdSer after ORP5/8 depletion or PI4KIIIa
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inhibition are still significantly lower than in parental cells, we would again conclude that
the Golgi pool of PtdSer is not a major contributor to KRAS PM localization. Further
investigation into how functional inhibition of ORP5 or ORP8 affects vesicular transport
is warranted.

Disruption of the PtdSer/PI4P exchange mechanism reduces tumorigenic
potential in animal models
Our in vitro observations were seen in vivo as well in multiple models. First, siRNA
silencing of orthologs of ORP5, ORP8 or the ER PI4P phosphatase, Sac1 phosphatase,
inhibited oncogenic let-60 (KRAS) signaling in C. elegans without adversely affecting
viability of the organism. Second, shRNA knockdown of either ORP protein significantly
inhibited tumor growth in our MiaPaCa-2 xenograft model. These results mirror our in
vitro confocal microscopy observations in MCF-7 single and double ORP5/8 knockdown
cells that showed no difference in the extent of PtdSer or KRAS mislocalization between
each ORP knockdown and no added effects in double knockdown cells. Additionally,
single and double ORP5/8 knockdown had no effect in our BxPC-3 xenograft model,
correlating with our C7 in vitro cell proliferation data which showed selective inhibition of
KRAS mutant but not KRAS wildtype cells [4]. This consistency between our in vitro and
in vivo data further confirms our claim that we are specifically inhibiting KRAS function
by inhibiting components of the PM PtdSer/PI4P homeostasis pathway, introducing
multiple new candidates to target KRAS-mutant tumors. This was further validated in our
immune-competent mouse models that showed largely reduced growth rate of
pancreatic tumors after knockout of either ORP5 or ORP8 compared to controls.
Because Cas9 is immunogenic and would interfere with our evaluation of ORP5 or ORP8
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loss on tumor growth in this model, we transiently transfected our cells with a plasmid
containing our guide RNA sequence and Cas9 and selected with puromycin for only 2
days to avoid integration of the plasmid into the host cell DNA. We then followed this by
single colony selection and verified knockout by Sanger sequencing of multiple colonies.
Our in vivo mouse experiments are in agreement with recent findings from our
collaborators showing that genetic loss of EFR3A, EFR3B or PI4KA, all of which
phenocopy loss of ORP5 or ORP8 by abolishing the PI4P PM-ER concentration gradient,
reduce tumor growth in xenograft mouse models of pancreatic cancer [386]. This is
particularly interesting, as this is the first study to implement a role of EFR3A for KRAS
function and its importance in cancer.

Expression levels of components of the PtdSer/PI4P exchange mechanism in
the context of human cancer cohorts
Work from Koga et al. [373] showed that PDAC patients with high ORP5
expression had a 36.4% one-year survival rate while those with low ORP5 expression
had a one-year survival rate of 73.9%. Additionally, they showed that siRNA knockdown
of ORP5 decreased the invasion potential of pancreatic cancer cells in matrigel, while
overexpression of ORP5 increased invasion. This correlated in patients, whereby high
ORP5 expression corresponded with invasion of cancer cells to the main pancreatic duct,
leading to early relapse [373, 387]. Through analyses of other patient cohorts in the
TCGA database, we found that this negative correlation between ORP5 expression level
and overall survival held true not only in PDAC but also in multiple other cancer types,
and we observed significantly increased ORP5 expression in KRAS mutant tumors
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compared to KRAS wild type tumors. We also found that high expression of ORP8
correlated with decreased patient survival in multiple cancers including PDAC.
We further confirmed the dependence of KRAS-mutant cancers on the
PtdSer/PI4P exchange mechanism by showing that these tumor cells have increased
expression of PI4KIIIa, its PM transporter EFR3A, and the PI4P phosphatase Sac 1
phosphatase. Additionally, this increased expression correlates with an increase in
KRAS expression, suggesting a link between their functions. In support of this, we found
that genetic alterations in PI4KA and EFR3A co-occur in several cancers. This is
encouraging since adaptor proteins such as EFR3A are difficult to target
pharmacologically, but kinases such as PI4KIIIa are not. Targeting PI4KIIIa rather than
EFR3A may also be a better option due to the possibility that EFR3B, the isoform of
EFR3A, may compensate and transport PI4KIIIa to the PM. Interestingly, we found that
genetic alterations between PI4KA and KRAS seem to be mutually exclusive. The
majority of PI4KA genetic alterations were missense mutations of unknown significance
(not classified as driver mutations). This may mean that the positive correlation we see
between PI4KA and KRAS mRNA expression level might be due to increased
transcription of PI4KA in pancreatic tumor cells rather than amplification of the gene itself.
However, genetic alterations of EFR3A (which are predominantly amplifications) cooccurred with KRAS genetic mutations to a significant degree, possibly indicating the
importance of sustained PM PI4KIIIa levels, and hence PI4P, in KRAS-mutants tumor
cells.
We showed the importance of EFR3A mechanistically as well, by showing that
loss of this gene resulted in the decrease of PM PtdSer levels due to the depletion of
PI4P generation on the PM leading to the functional inhibition of ORP5/8. As expected,
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this led to decreased KRAS PM localization and nanoclustering. This correlates with data
showing that PI4KA loss also leads to depleted PI4P and PtdSer levels on the PM [386].
We also showed that this effect is indeed mediated by PtdSer levels as supplementation
with exogenous PtdSer in EFR3A knockout cells rescued KRAS PM localization and
nanoclustering. Additionally, we showed that all components of the EFR3A adapter
complex (EFR3A, EFR3B, FAM126A and TTC-7A) colocalized with KRAS on the PM
and loss of any of these components or PI4KIIIa was shown by others to reduce the
amount of KRAS on the PM by immunofluorescence and biochemical fractionation [386].
It has also been shown that tethering PI4KIIIa, similar to addition of exogenous PtdSer,
restored KRAS PM localization in EFR3A knockout cells as assessed by confocal
microscopy [386], indicating that KRAS mislocalization in these cases is indeed a
specific consequence of inhibiting PI4KIIIa enzymatic function and, thus PI4P and
PtdSer homeostasis on the PM. Moreover, loss of EFR3A or PI4KIIIa has been shown
to decrease p-ERK and p-AKT levels, which were rescued by tethering PI4KIIIa to the
PM [386].

PI4KIIIa as a novel therapeutic target for the treatment of KRAS-dependent
cancers
Overexpression of PI4KIIIα results in increased localization of ORP5/8 to PM-ER
MCSs; conversely, inhibition of PI4KIIIα using the small molecule inhibitor A1 [388] leads
to the dissociation of these complexes. It has also been reported that PI4KIIIα inhibition
decreased the amount of ORP5 and ORP8 localized to the PM [355]. In support of the
rationale of targeting this protein in cancer, PI4KIIIα has been shown to contribute to the
invasion and metastasis of pancreatic cancer in a difference analysis screen [389], and
to the acquired resistance against gemcitabine in pancreatic cancer [390]. Additionally,
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studies showed that prolonged overexpression of PIP5K1b, which converts PI4P to PIP2,
caused a redistribution of PI4P to endosomal and Golgi compartments, effectively
reducing PI4P PM levels and therefore PIP2 PM levels by limiting substrate availability.
This in turn led to a reduction of PtdSer levels on the PM, further validating the rationale
of targeting PI4KIIIα to reduce PI4P, and hence PtdSer, PM levels to inhibit KRAS
signaling [355].

Several pan and selective PI4K inhibitors have been synthesized

(reviewed in [323]). The tool compound demonstrating the most selectivity towards
PI4KIIIα is the small molecule C7 (IC50 against PI4KIIIα, PI4KIIIg, PI3K: 6.3 nM, 1,250
nM, and inactive, respectively). In accordance with findings from Sohn et al., we showed
that treating MDCK cells with C7, resulted in redistribution of PtdSer, and hence KRAS,
from the PM to endomembranes in a dose-dependent manner. Our results are also in
accordance with others who found a 50% reduction in overall PtdSer levels and a
depletion of PtdSer levels at the PM in response to PI4KIIIα inhibition or PI4KA knockout
[321, 364]. The decrease of PtdSer synthesis was due to the accumulation of PtdSer at
the ER, and its consequent negative feedback inhibition on PtdSer synthase I and II.
Importantly, we also found that C7 selectively inhibited the proliferation of pancreatic
cancer cell lines, with KRAS-dependent lines displaying increased sensitivity compared
to KRAS-independent lines. KRAS wildtype cells were only affected at high
concentrations, and immortalized normal pancreatic cells were unaffected even at the
highest concentrations tested. We showed no increased effect on KRAS-WT BxPC-3
cells when combining C7 with LY3214996, Trametinib, or Copanlisib (inhibitors of
ERK1/2, MEK and PI3K, respectively). However, we saw a synergistic effect in PANC-1
and MiaPaCa-2 cells and an additive effect in MoH cells. MoH cells were the most
sensitive cell line to single treatment of each of the above-mentioned drugs. This may
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explain the additive effects we see in this cell line. Additivity between drugs usually
occurs when both drugs have the same target, and since that is not the case with our
tested compounds, another explanation is that the drug concentrations needed to elicit
the desired effect are smaller than the concentration needed to inhibit 50% of target
receptors [391]. We speculate that the reason MoH cells have consistently been the most
sensitive to treatment in our experiments is due to the KRAS-G12R mutation these cells
harbor. As mentioned in Chapter 1, cell lines with KRAS-G12R mutations cannot activate
the PI3K/AKT pathway to induce macropinocytosis due to the impaired binding of this
KRAS mutant to the p110a subunit of PI3K, and has been shown to be more vulnerable
against MAPK inhibitors compared to cell lines harboring KRAS-G12V or -G12D
mutations [229]. Additionally, KRAS-G12R mutant cells depend on the upregulation of
PI3Kg signaling to support macropinocytosis [229]. Because of that, we see the most
profound effect when C7 is combined with Copanlisib, a pan PI3K inhibitor. These
observations are consistent with our ORP5/8 knockdown data where MoH cells showed
the most severe effect in regards to viability and loss of anchorage-independent growth.
While other cell lines may compensate for the loss of KRAS-dependent activation of
MAPK and PI3K/AKT pathways by increasing KRAS-independent activation of
PI3K/AKT, MoH cells cannot -at least not efficiently-. Looking back at Figure 13, we see
that even parental MoH cells lacked detectable pThr308 levels, indicating the lack of
PI3K activation. Collectively, these observations may justify the use of KRAS-G12R
mutations as a marker for sensitivity towards PI4KIIIa inhibition.
Our results are echoed by the work of Adhikari et al. who showed that knockout
of either EFR3 isoform or PI4KA decreased in vitro cell proliferation, colony formation
and anchorage-independent growth in a panel of pancreatic cancer cell lines [386]. The
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importance of the immediate and upstream components of the PtdSer/PI4P exchange
mechanism in PDAC are also depicted in the increased mRNA levels of these genes in
human tumors compared to normal tissue and, more specifically, in KRAS-mutant tumors
over KRAS-WT tumors. Though G12C mutations are not the most common in PDAC,
they are the predominant mutation found in KRAS-mutant non-small cell lung cancers
and our mechanism of targeting KRAS can be extrapolated, theoretically, to any KRASdependent tumor. C7 showed synergistic response when combined with the KRAS
G12C-specific inhibitor Sotorasib and had potent effects on inhibiting proliferation of
KRAS-G12C mutant lung adenocarcinoma cell lines [386]. This finding may prove
particularly appealing as KRAS G12C-specific inhibitors are progressing through clinical
trials of lung and colorectal cancers [176, 177, 392]. However, mechanisms of resistance,
such as upregulation of heparin-binding epidermal growth factor (HBEGF), aurora kinase
A (AURKA) and KRAS have already been reported [179]. Therefore, inhibition may offer
protection against Sotorasib-induced resistance in KRAS-G12C cancers.

Repurposing Simeprevir for the treatment of KRAS-dependent cancers
We identified another PI4KIIIα inhibitor, Simeprevir, which selectively and potently
mislocalized KRAS and PtdSer from the PM. In comparison to 30µM of C7, 200nM of
Simeprevir was sufficient to significantly mislocalize KRAS and PtdSer from the plasma
membrane. It has been reported that Simeprevir treatment also leads to decreased levels
of p-PKC and p-AKT [393]. Simeprevir is an alluring drug candidate because of its
previously established safety profile as it is a FDA-approved anti-viral agent used to treat
Hepatitis C. Simeprevir inhibits the viral NS3/4A protease [383] but was recently also
found to inhibit host PI4KIIIα [394] which contributes towards its anti-viral properties
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because PI4KIIIα enzymatic activity is stimulated by viral proteins in HCV-infected cells
to increase PI4P production which is essential for the formation of the viral replication
complex [383]. It is important to note that PI4KIIIα function in uninfected host cells was
not compromised as the dosage needed to eliminate HCV-infected cells is far lower than
that needed to affect normal cells due to the virally-stimulated PI4KIIIα activity in infected
cells [383]. Therefore, we aimed to repurpose Simeprevir for the treatment of KRASdriven cancers. Corsello et al. developed a drug repurposing resource called DepMap
(https://depmap.org/repurposing) that surveyed 4,518 drugs for their growth-inhibitory
activity in 578 human cancer cell lines. They found that the majority of drugs that
selectively inhibited cancer cell lines were non-oncology drugs [395]. Analyzing this
repository, we found that not only was Simeprevir a hit, but that 21/34 pancreatic, 18/34
colorectal and 52/88 NSCLC cancer lines were deemed sensitive to 2.5µM Simeprevir
treatment. We also showed that Simeprevir reduced anchorage-independent growth and
colony formation in a dose-dependent manner in our PDAC cell lines. In our clonogenic
assays, PANC-1 was particular sensitive to combination treatments of Simeprevir with
low doses of LY3214996 or Copanlisib (additive effects). Simeprevir + LY3214996
treatment also had a clear additive effect in MiaPaCa-2 cells. While low doses of
Trametinib increased clonogenic potential in these cells (a biphasic response),
combination with Simeprevir reduced it to levels between that of Simeprevir alone and
Trametinib alone. A synergistic effect was seen when combining Simeprevir with either
LY3214996 or Copanlisib in MoH cells.
We moved forward in our in vivo experiments with Simeprevir as opposed to C7
since C7 remains a new small tool compound that has not been previously tested on
animals. We showed the effects of PI4KIIIa inhibition on KRAS signaling in vivo using
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the previously explained let-60 multi-vulva C. elegans model system. Both Simeprevir
and C7 dose-dependently inhibited let-60 signaling, reverting the multivulva phenotype
back to the wildtype single vulva phenotype without any observed toxicity on the
organisms, even at the highest concentrations tested. Simeprevir also reduced tumor
growth in mice with a stronger effect when combined with Trametinib or Copanlisib. Initial
higher dosages proved to be too toxic, especially in the Simeprevir+Copanlisib treatment
group mirroring what we had seen in vitro. This is not too surprising as simultaneously
targeting two lipid kinases at such doses would likely cause significant disruption of lipid
metabolism, cellular membranes and organelle integrity. Homozygous PI4KA conditional
knockout mice showed distended abdomens and gastrointestinal abnormalities and had
to be euthanized within a week of induction. However, heterozygous PI4KA conditional
knockout mice were healthy [396]. The difference seen between the homozygous and
heterozygous conditions may be representative of high vs low doses of PI4KIIIa
inhibitors. We have also seen the distended abdomen phenotype in some of our mice
treated with both Simeprevir and Copanlisib. The results seen with the conditional
knockout mice were used by the authors to refute the possibility of using PI4KIIIa
inhibitors for the treatment of Hepatitis C. However, a year after the study was published,
Simeprevir (tradename Olysio) was approved by the FDA for the treatment of Hepatitis
C, and later in 2014 was approved in combination with another antiviral agent for a subset
of Hepatitis C infections. In 2017, Simeprevir-induced PI4KIIIα inhibition was found to
increase radiosensitivity in diverse cancer cell lines in vitro as well as in immune
competent and nude mouse models of breast and brain cancer, leading to the
recommendation of repurposing this FDA-approved anti-viral agent to be put to use in a
cancer treatment setting [393]. Thus, targeting PI4KIIIα is tolerated in these animals at
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concentrations that result in anti-tumor effects. We also saw no negative affect on viability
in our worms treated with C7 or Simeprevir. Although work by Balla et al. claimed that
safe pharmacological targeting of PI4KIIIα is not feasible [397], we argue against that
claim for C7 and Simeprevir. In their paper, they synthesized several PI4K inhibitors, all
of which inhibited PI4KIIIα, PI4KIIIβ, PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ to differing
degrees. To date, C7 seems to be the most selective PI4KIIIα inhibitor synthesized, with
a log IC50 of 8.2 for PI4KIIIα, 5.9 for PI4KIIIβ, and no activity against PI3Ks [264, 323].
Out of the 5 compounds synthesized by Balla et al., only G1, had an IC50 difference
between PI4KIIIα and PI4KIIIβ comparable to that of C7. Additionally, G1 also inhibited
PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ at similar potencies; which may be why the drugs tested
in this paper were so toxic. Furthermore, the authors reported that gastric mucosal
epithelial degeneration occurred with oral administration of compounds tested at the
highest dosage, some of which inhibited PIP2 resynthesis causing sudden cardiac arrest.
Mice treated at lower doses remained viable and had GI abnormalities to differing
degrees from mild to severe which the authors possibly account to the oral administration
of the drug [397]. Finally, their and others’ genetic experiments involved a complete gene
knockout or mutation of the kinase domain (functional knockout) of PI4KIIIα, leading to
sudden death of the animals [396, 397]. We have shown that C7 had no effect on
immortalized “normal” human HPNE pancreatic cells and was selective for pancreatic
cancer cells along 11 different concentrations tested. Moreover, KRAS-mutant
pancreatic cells were more sensitive to the drug, with IC50s in the nM range compared
to KRAS WT cancer cells in the µM range. This mirrors the use of Simeprevir at doses
small enough to affect only HCV-infected cells that are more sensitive to PI4KIIIα
inhibition, indicative of a therapeutic window for susceptible cells. And just as HCV-
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infected cells have higher PI4KIIIα activity, our patient tumor analysis showed us that
tumor cells have increased levels of PI4KIIIα. Hence, we believe that we can utilize a
small enough dosage of C7 or Simeprevir to elicit the desired results on tumor cells while
having minimal side effects on any normal tissues in in vivo models. Furthermore,
PI4KIIIα is not commonly mutated in cancer, allowing us to be cautiously optimistic of a
low mutability rate of this gene [322]. Additionally, PI4KIIIα inhibition decreased pAKT
levels by decreasing PIP3 PM levels in breast cancer cells; hence, it can act in KRAS
mutant cells as a target to simultaneously inhibit both MAPK and PI3K pathways which
is an attractive notion given that 93% of PIK3CA mutations in PDAC co-occur with KRAS
mutations [82, 393]. Therefore, PI4KIIIα has merit as a novel treatment target for KRASdependent tumors that warrants further research. Finally, it would be interesting to
evaluate whether Simeprevir can be used as a preventative measure, as a recent
prospective study evaluating the incidence of non-hepatic cancers in patients with
chronic hepatitis C, found that triple or all-oral therapy treatments (all of which included
Simeprevir) decreased the risk of developing pancreatic and lung cancer incidences by
45% and 25%, respectively. Importantly, these treatments had no significant effect in
reducing the risk of other cancers; and dual therapy of interferon with ribavirin had did
not reduce cancer risk of any cancer type [398].
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CHAPTER 7: FUTURE DIRECTIONS
Further studies quantifying levels of different PM PI species following our drug
treatments in vitro as well as RNAseq analysis of tumors derived from our mice
experiments are warranted to observe and understand the changes occurring in lipid
levels as well as molecular signaling pathways post-treatment. The increase in
expression levels of the components of the PtdSer/PI4P exchange mechanism in human
cancers can be a means to increase the amount of PM PtdSer to either: 1) facilitate the
localization of more KRAS molecules on to the PM (due to increased KRAS expression
in these tumors) and/or 2) to possibly retain active KRAS on the PM for longer periods
of time. Studies that look into KRAS PM residence time in cells lacking or overexpressing
components of the PtdSer/PI4P exchange mechanism and their parental counterparts
could shed some light on this matter. Additionally, KRAS residence time in PI4KIIIainhibitor treated and non-treated cells would also be a crucial experiment to perform.
Though our analysis of genetic alterations and expression levels were focused on
pancreatic tumors (as >90% of PDAC cases harbor a KRAS mutation), it will be important
to explore what occurs in other cancers such as lung and colorectal cancers and, if
differences are seen, to analyze that data further. Some questions to be addressed are:
is it just KRAS mutation status that promotes these changes or does the tumor
microenvironment and cancer type also have a role? Are the same results seen in tumors
harboring different KRAS mutations? Are there certain driver mutations, such as P53
loss, that must also be present along with KRAS mutations to utilize the PtdSer/PI4P
exchange mechanism to its fullest, possibly by increasing the transcription rate of the
genes involved?
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Additional in vivo experiments to optimize the dosage and administration
frequency for Simeprevir alone and in combination with MAPK and PI3K inhibitors to
inhibit tumor growth without unacceptable toxicity must be done. Previous attempts for
the development of PI4K inhibitors for the treatment of Hepatitis C showcase the difficulty
of dosing PI4K inhibitors [393, 397]. Of course, we realize that the required dosing of
Simeprevir will change depending on what drug we are combining it with; for example,
we saw more toxicity when combining Simeprevir with the PI3K inhibitor Copanlisib than
with the MEK inhibitor Trametinib. Preclinical development of C7 should also be explored
as another PI4KIIIa inhibitor since it has not been tested previously in vivo. Moreover, a
deeper look into targeting Sac 1 phosphatase as a means of inhibiting oncogenic KRAS
signaling is warranted.
In conclusion, this work was the first to showcase the link between KRAS and
ORP5/8 and introduce the PtdSer/PI4P exchange mechanism as a targetable pathway
for the inhibition of KRAS function in cancer. We excitingly propose the repurposing of
Simeprevir for the treatment of KRAS-mutant cancers, and the development of other
PI4KIIIa inhibitors to target these cancers. We hope this work serves as a stepping stone
towards the realization of that goal and opens up a new avenue by which to target KRASmutant tumors.
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